ВЫСОКОКАЛОРИЙНАЯ ПИТАТЕЛЬНАЯ КОМПОЗИЦИЯ С ВЫСОКИМ СОДЕРЖАНИЕМ БЕЛКА, ВКЛЮЧАЮЩАЯ КОЛЛАГЕН

Группа изобретений относится к питательной композиции для предупреждения и лечения белково-энергетического нарушения питания и способу её получения. Питательная композиция для предупреждения и лечения белково-энергетического нарушения питания, включающая белковый компонент, липидный компонент, углеводный компонент, минералы, витамины и воду, причем белковый компонент включает два различных источника белка: первым источником белка является гидролизат коллагена со средней молекулярной массой Mw от 1000 Да до 6000 Да; второй источник белка, выбранный из молочных белков; причем питательная композиция имеет рН в интервале 5,5-9,0, при определенном соотношении компонентов в композиции. Способ получения питательной композиции. Вышеописанная группа изобретений позволяет создать гомогенную питательную композицию, имеющую как высокую калорийную ценность, так и большое количество белка в небольшом объеме. 2 н. и 12 з.п. ф-лы, 11 табл., 5 пр.

КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ СТАБИЛЬНОСТИ РЕАКЦИОННОСПОСОБНЫХ АМИНОКИСЛОТ В ПИЩЕВОМ МАТРИКСЕ

ПИТАТЕЛЬНАЯ ДОБАВКА

Compositions

USE OF ALPHA ALPHA TREHALOSE ONES AS ENERGY SOURCE

Edible energy composition

The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested.

Deuterated caffeine and uses thereof

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

FOOD SUPPLEMENT, USES THEREOF, METHOD FOR FOOD SUPPLEMENTATION, AND ORAL SPRAY

The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

Nutritional compositions

The invention relates to compositions comprising novel blends of nutritional ingredients and solid, semi-solid and beverage compositions comprising such blends. In particular, this invention relates to rehydration, energy and recovery beverages (e.g. sports drinks), compositions for support of weight management, as well as digestive, bone, cognitive and heart health.

비환원성 말단의 불포화형 만뉴론산 올리고당(ＯｌｉｇｏＭ)을 유효성분으로 포함하는 운동 능력 개선용 조성물

... 본 발명은 (a) 만뉴론산 올리고당의 치료학적 유효량; 및 (b) 식품학적으로 허용되는 담체를 포함하는 운동 능력 개선용 조성물을 제공한다. 상기 조성물은 단시간에 운동 능력 개선 효과를 나타내며, 활성 물질의 제조가 용이하고 경제적인 이점을 갖는다.

NUTRITIONAL COMPOSITIONS

ПРИМЕНЕНИЕ D-РИБОЗЫ ДЛЯ УСИЛЕНИЯ ПРОЦЕССА АДАПТАЦИИ К ФИЗИЧЕСКОМУ СТРЕССУ

КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ СТАБИЛЬНОСТИ РЕАКЦИОННОСПОСОБНЫХ АМИНОКИСЛОТ В ПИЩЕВОМ МАТРИКСЕ

... 1. Твердый пищевой продукт, содержащий по меньшей мере один источник твердых ингредиентов, выбранный из группы, состоящей из бета-глюкановых хлопьев, воздушного риса, плющеной овсяной крупы, кусочков фруктов и их сочетаний; и по меньшей мере одну реакционноспособную аминокислоту в связующем материале, практически не содержащем восстанавливающих сахаров.2. Твердый пищевой продукт по п. 1, в котором реакционноспособную аминокислоту выбирают из группы, состоящей из аланина, аргинина, аспарагина, аспарагиновой кислоты (аспартата), цитруллина, цистеина, глутаминовой кислоты (глутамата), глутамина, глицина, гистидина, гидроксипролина, гидроксисерина, гидрокситирозина, гидроксилизина, изолейцина, лейцина, лизина, метионина, фенилаланина, пролина, серина, таурина, треонина, триптофана, тирозина, валина и их сочетаний.3. Твердый пищевой продукт по п. 1, в котором реакционноспособная аминокислота является бета-аланином.4. Твердый пищевой продукт по п. 1, в котором реакционноспособная аминокислота ...

Modulation of energy expenditure

Energy-supplementing saccharide source and its uses

COMPOSITION FOR PERCUTANEOUS ENERGY ABSORPTION

The present invention relates to a composition for percutaneous energy absorption, and more particularly, to a composition for percutaneous energy absorption including caffeine and taurine to provide energy through percutaneous absorption. The composition for percutaneous energy absorption according to the present invention contains caffeine, taurine and sodium hyaluronate. The composition for percutaneous energy absorption according to the present invention is easy to carry when compared to energy drinks, provides a fatigue relieving effect owing to the caffeine without ingesting of glucose, provides a drowsiness prevention effect by inducing vigorous metabolism and raising concentration, and may provide a skin moisturizing effect, so may replace energy drinks. COPYRIGHT KIPO 2017 (AA) Blood caffeine concentration (BB) Average ...

COMPOSITION

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts. 112-. (canceled)13. A composition comprising: (i) components having a molecular weight of less than 1000; and', '(ii) contains one or more of a nucleoside; a glycosylated phenolic acid or a phenolic ester, or derivative thereof; or a glycosylated flavonoid with platelet aggregation inhibiting activity; and, '(a) a water-soluble extract of fruit of the Solanaceae family with activity for inhibiting platelet aggregation, wherein the extract comprises(b) a source of dietary nitrate or a precursor of endogenous nitric oxide,wherein the composition is in a form of a nutraceutical product, drink, food substance, food supplement, gel, powder, food bar or dispersable tablet.14. The composition according to wherein the composition comprises (1) is colourless or straw-coloured;', '(2) consists of components having a molecular weight of less than 1000; and', (i) a glycosylated phenolic acid or a phenolic ester;', '(ii) a glycosylated flavonoid; and', '(iii) a nucleoside, '(3) contains], '(a) a water-soluble tomato extract, wherein the extract(b) an exogenous source of dietary nitrate or a precursor of endogenous nitric oxide, wherein the exogenous source comprises a water-based extract of fresh fruit or vegetable tissue, wherein the fruit or vegetable contains levels of nitrate sufficiently high to result in final extract concentrations of 7.5 g/l nitrate or greater and wherein the precursor is selected from citrulline, glutamine or arginine; and(c) folic acid or a metabolite of folic acid which is 5-methoxytetrahydrofolate or tetrahydrofolate.15. The composition according to wherein the source of dietary nitrate (b) is selected from a water-soluble extract from swiss chard ...

High caloric, high protein nutritional formula comprising collagen

A nutritional composition comprises a protein component, a lipid component and a carbohydrate component, minerals, vitamins and water, wherein the protein component comprises at least two different protein sources; wherein the first protein source is hydrolysed collagen; the lipid component provides at least 30 EN % of the total energy of the composition and the first source of protein represents 35-95 wt % based on the total weight of the protein component. The nutritional composition provides a homogeneous emulsion of high energy density (e.g. at least 3 kcal/mL) and high protein density (e.g. at least 14 g/100 mL).

ПРИМЕНЕНИЕ D-РИБОЗЫ ДЛЯ УСИЛЕНИЯ ПРОЦЕССА АДАПТАЦИИ К ФИЗИЧЕСКОМУ СТРЕССУ

Настоящее изобретение относится к медицине, а именно к физиологии, и касается улучшения адаптации к физическим нагрузкам. Для этого перед, во время и после выполнения физических упражнений перорально вводят 6-10 г D-рибозы. Способ обеспечивает повышение работоспособности за счет улучшения адаптации к физическому стрессу, причем этот эффект наиболее выражен у нетренированных субъектов. 4 з.п. ф-лы, 5 табл., 1 ил.

Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source comprising whey protein preferably containing whey protein micelles, and a source of casein, and optionally other proteins. The inventive heat sterilized enteral composition preferably has a cysteine content of at least 1.2 % by weight of the protein source. The present invention is furthermore directed to a process for preparing such a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein comprising whey protein containing whey protein micelles and casein and optionally other proteins. The process comprises the steps of: (i) Providing an aqueous solution of a protein source comprising whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization ...

HEAT STERILIZED HIGH PROTEIN ENTERAL COMPOSITIONS WITH WHEY PROTEIN WHICH COMPRISES WHEY PROTEIN MICELLES AND A SOURCE OF CASEIN

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source consisting of whey protein containing whey protein micelles and a source of casein. The inventive heat sterilized enteral composition preferably has a cysteine content of 1.2 to 2.4% by weight of the composition. The present invention is furthermore directed to a process for preparing a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein consisting of whey protein containing whey protein micelles and casein, which comprises the steps of: (i) Providing an aqueous solution of a protein source consisting of whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization treatment step; (iv) Performing a heat treatment step; (v) Optionally ...

BEER COMPOSITION AND METHOD OF MAKING SAME

A beer composition comprising a hydration additive which includes a coconut extract and a salt additive is disclosed. The beer composition may provide a hydrating effect or a feeling of hydration upon consumption. The coconut extract may be in the form of a frozen coconut concentrate that can be diluted with water to form a coconut solution. The coconut solution may be added during the brewing process together with the salt additive in a mixture or may be added separately or sequentially. Typically the salt additive is in the form of sodium chloride and may contain other optional salts.

LACTOBACILLUS RHAMNOSUS CBT LR5 STRAIN FOR PREVENTING OR TREATING OBESITY AND METABOLIC SYNDROME CAUSED BY OBESITY, AND COMPOSITION COMPRISING SAME

The present invention relates to a Lactobacillus rhamnosus CBT LR5 (accession NO. KCTC 12202BP) strain for treating or preventing obesity and metabolic syndromes caused by obesity, and a pharmaceutical composition and an anti-obesity food composition for preventing or treating obesity and metabolic syndromes caused by obesity, comprising the strain. COPYRIGHT KIPO 2016 ...

processo de obtenção de barras energéticas a partir de ingredientes naturais

Nutritional gel composition

PROTEIN BAR

The invention relates to a protein bar which is formed from a shapeable mass that contains proteins and/or protein hydrolysates. The shapeable mass contains a collagen hydrolysate having an average molecular mass of up to 1700 Da as a protein hydrolysate.

EDIBLE ENERGY COMPOSITION

The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested.

ENERGY-SUPPLEMENTING SACCHARIDE SOURCE AND ITS USES

Trehalose, prepared by the method containing a step of allowing a non-reducing saccharide-forming enzyme to act on a partial starch hydrolysate exhibiting a reducing power, is advantageously used as an energy-supplementing saccharide source and used in energy-supplementing compositions as an effective ingredient. The saccharide source and compositions can be suitably used as pharmaceutical compositions for supplementing energy for living bodies without a fear of causing side effects.

КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ СТАБИЛЬНОСТИ РЕАКЦИОННОСПОСОБНЫХ АМИНОКИСЛОТ В ПИЩЕВОМ МАТРИКСЕ

Изобретение относится к продуктам и способам, обеспечивающим стабильность функциональных аминокислот в пищевых матриксах. Предложен твердый пищевой продукт, содержащий по меньшей мере один источник твердых ингредиентов, выбранный из группы, состоящей из бета-глюкановых хлопьев, воздушного риса, плющеной овсяной крупы, кусочков фруктов и их сочетаний, и по меньшей мере одну реакционноспособную аминокислоту, которая является бета-аланином или карнозином, в связующем материале, практически не содержащем восстанавливающих сахаров, при этом твердый пищевой продукт представляет собой твердый пищевой батончик, на порционный размер которого приходится от 1,0 г до 3,5 г реакционноспособной аминокислоты. Также предложен способ изготовления твердого пищевого продукта с повышенной стабильностью реакционноспособной аминокислоты, включающий объединение реакционноспособной аминокислоты, которая является бета-аланином или карнозином, со связующим материалом, практически не содержащим восстанавливающих ...

ПИТАТЕЛЬНАЯ ДОБАВКА

Изобретение относится к технологии производства спортивных напитков. Предложены четыре варианта применения питательных добавок для использования в качестве спортивных напитков. В первом варианте твердая питательная добавка содержит от 0,2 до 16 мас.% альгината, от 0,12 до 12 мас.% пектина и от 75 до 99 мас.% активных ингредиентов. Активные ингредиенты выбирают из одного или более ингредиентов, включающих сахара, сложные углеводы, минеральные соли и аминокислоты. Добавку растворяют в воде для использования в качестве спортивного напитка. Во втором варианте жидкая питательная добавка содержит от 0,05 до 2,0 мас.% альгината, от 0,03 до 1,5 мас.% пектина и от 5 до 25 мас.% активных ингредиентов, остальное - вода. Согласно изобретению заявленные питательные добавки под воздействием низкого рН желудочного сока образуют в желудке потребителя гидрогели. Изобретение обеспечивает отсроченное высвобождение сахаров и других активных ингредиентов в желудке потребителя, не вызывая при этом нежелательных ...

ВЫСОКОКАЛОРИЙНАЯ ПИТАТЕЛЬНАЯ КОМПОЗИЦИЯ С ВЫСОКИМ СОДЕРЖАНИЕМ БЕЛКА, ВКЛЮЧАЮЩАЯ КОЛЛАГЕН

Compositions

A composition comprising (a) a water-soluble extract of fruit of the solanaceae family, preferably tomato, with activity for inhibiting platelet aggregation, wherein the extract comprises: (i) components having a molecular weight of less than 1000; and contains one or more of a nucleoside; a glycosylated phenolic acid or a phenolic ester, or derivative thereof; or a glycosylated flavonoid with platelet aggregation inhibiting activity; (b) a source of dietary nitrate, preferably swiss chard, rocket, spinach, rhubarb, strawberry and lettuce, or a precursor of endogenous nitric oxide; and (c) folic acid or metabolites thereof is provided. Preferably the glycosylated phenolic acid or phenolic ester is selected from caffeic acid glucoside, p-coumaric acid hexose/dihydrokaempferol hexose, ferulic acid glycoside, a p-coumaric acid derivative, a glycosylated cinnamic acid or derivative thereof selected from caffeoyl-4-O-quinic acid, caffeoyl-4-O-glucoside, coumaroyl-4-O-glycoside and coumaroyl- ...

Compositions

Protein food product comprising D-allulose

The present invention pertains to a solid food product comprising a D-allulose syrup and a native protein. This invention is also directed to the use of this solid food product as a protein supplement for dietarians, athletes and bodybuliders. This invention also pertains to the use of D allulose to reduce hardening of a protein food product, as an aid for quick hydration and as an aid for improving the cohesiveness of a dough.

신체적 스트레스에 대한 순응을 증진시키기 위한 D-리보오스의 용도

D-리보오스를 경구 투여함으로써 신체적 스트레스에 대한 순응을 개선하는 방법들 및 신체 운동에 대한 순응을 개선하기 위해 D-리보오스를 경구 투여하는 방법들이 개시된다.

Nutritional compositions

Compositions and methods for the stability of reactive amino acids in a food matrix

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

Protein food product comprising D-allulose

The present invention pertains to a solid food product comprising a D-allulose syrup and a native protein. This invention is also directed to the use of this solid food product as a protein supplement for dietarians, athletes and bodybuilders. This invention also pertains to the use of D-allulose to reduce hardening of a protein food product, as an aid for quick hydration and as an aid for improving the cohesiveness of a dough.

Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

HEAT STERILIZED HIGH PROTEIN ENTERAL COMPOSITIONS WITH WHEY PROTEIN WHICH COMPRISES WHEY PROTEIN MICELLES AND A SOURCE OF CASEIN

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source comprising whey protein preferably containing whey protein micelles, and a source of casein, and optionally other proteins. The inventive heat sterilized enteral composition preferably has a cysteine content of at least 1.2 % by weight of the protein source. The present invention is furthermore directed to a process for preparing such a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein comprising whey protein containing whey protein micelles and casein and optionally other proteins. The process comprises the steps of: (i) Providing an aqueous solution of a protein source comprising whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization ...

PROTEIN FOOD PRODUCT COMPRISING D-ALLULOSE

The present invention pertains to a solid food product comprising a D-allulose syrup and a native protein. This invention is also directed to the use of this solid food product as a protein supplement for dietarians, athletes and bodybuilders. This invention also pertains to the use of D-allulose to reduce hardening of a protein food product, as an aid for quick hydration and as an aid for improving the cohesiveness of a dough.

염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 기능성 음료

... 본 발명은 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 유효성분으로 포함하는 기능성 음료에 관한 것이다. 본 발명의 기능성 음료는 섭취 시 입안에 청량감을 부여할 뿐만 아니라, 젖산과 활성산소 등과 같은 피로물질을 효과적으로 제거하고 체내 ATP 생성을 증가시켜, 생활에 활력을 부여하고 운동능력과 인지기능을 향상시킬 수 있다. 본 발명의 기능성 음료는 항염과 면역기능 유지 또는 저하 개선 효과를 나타낼 수 있다.

COMPOSITION AND USE

The invention provides the simultaneous, separate or sequential feeding or administration of a carnitine substance (e.g. L-carnitine) with an agent for increasing the blood/plasma insulin concentration. The agent may be protein, carbohydrate or one or more amino acids or a combination of such nutrients. The co-administration or co-feeding of the carnitine substance and the agent provide for the reduction of whole body fat mass, particularly associated with excess dietary energy intake. The disclosed co-administration may also provide for the treatment of insulin resistance, fat oxidation disorders or obesity, and for increasing energy expenditure and fat metabolism. Compositions and kits containing the carnitine substance and the agent are provided, as are methods of treatment employing the co-administration or feeding of the carnitine substance and the agent. Also described is the upregulation of several genes in response to the treatments of the invention, including ACAT1, PNPLA2, PDK2 ...

COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

LOW VISCOSITY, HIGH CALORIC DENSITY NUTRITIONAL COMPOSITIONS

Liquid nutritional compositions including both soy protein and dairy protein demonstrate enhanced rheological properties. By suitable selection of the types and amounts of these proteins, high caloric density products can be obtained without adversely affecting other desirable properties such as nutritional value, stability, taste, and mouthfeel.

Nutritional gel composition

A nutritional gel composition comprises starch and at least one further energy substrate. The method of preparing the gel composition comprises the steps of: combining the starch with water to form a starch and water mixture; heating the starch and water mixture to a temperature in the range of 60-100 ºC; homogenising the starch and water mixture at a pressure in the range 20-400 MPa or using a sonic homogeniser; and adding the energy substrate at a temperature in the range of 60-100ºC. The energy substrate may be a carbohydrate. There may be two or more energy substrates and they may be maltodextrin and fructose. The composition may comprise gellan gum. The composition provides multiple rapidly absorbed energy sources without loss of stability for greater control over rate of energy delivery and availability to muscles.

Compositions

Nutritional gel composition

Energy-supplementing saccharide source and its uses

Compositions

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts.

Food supplement, uses thereof, method for food supplementation, and oral spray

The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

COMPOSITIONS

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts.

USE OF D-RIBOSE TO ENHANCE ADAPTATION TO PHYSICAL STRESS

Methods of improving adaptation to physical stress by administering D-ribose and methods of administering D-ribose to improve adaptation to physical exercise.

CURCUMIN COMPOSITIONS AND USES THEREOF

Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic ...

COMPOSITIONS AND METHODS FOR THE STABILITY OF REACTIVE AMINO ACIDS IN A FOOD MATRIX

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

Compositions and methods for the stability of reactive amino acids in a food matrix

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source comprising whey protein preferably containing whey protein micelles, and a source of casein, and optionally other proteins. The inventive heat sterilized enteral composition preferably has a cysteine content of at least 1.2 % by weight of the protein source. The present invention is furthermore directed to a process for preparing such a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein comprising whey protein containing whey protein micelles and casein and optionally other proteins. The process comprises the steps of: (i) Providing an aqueous solution of a protein source comprising whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization ...

Curcumin compositions and uses thereof

Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic ...

Curcumin compositions and uses thereof

Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic ...

COMPOSITIONS AND METHODS USING A COMBINATION OF CALCIUM AND AT LEAST ONE OF OLEUROPEIN OR METABOLITE THEREOF

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

NUTRITIONAL SUPPLEMENTS

Verwendung von Alpha-alpha-trehalose als Energiequelle

Characterization of rice

Use of D-ribose to enhance adaptation to physical stress

Methods of improving adaptation to physical stress by administering D-ribose and methods of administering D-ribose to improve adaptation to physical exercise.

High caloric, high protein nutritional formula comprising collagen

A nutritional composition comprises a protein component, a lipid component and a carbohydrate component, minerals, vitamins and water, wherein the protein component comprises at least two different protein sources; wherein the first protein source is hydrolysed collagen; the lipid component provides at least 30 EN % of the total energy of the composition and the first source of protein represents 35-95 wt% based on the total weight of the protein component. The nutritional composition provides a homogeneous emulsion of high energy density (e.g. at least 3 kcal/mL) and high protein density (e.g. at least 14 g/100mL).

NUTRITIONAL SUPPLEMENTS

The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

COMPOSITIONS AND METHODS FOR THE STABILITY OF REACTIVE AMINO ACIDS IN A FOOD MATRIX

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

SUSTAINED RELEASE OF NUTRIENTS IN VIVO

Nutritional compositions delivered in vivo in a time controlled manner sustainable over long periods of time, provide enhancing athletic performance, increased hand/eye co- ordination and concentration on the task at hand.

Compositions and methods for the stability of reactive amino acids in a food matrix

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

Compositions and methods for the stability of reactive amino acids in a food matrix

The present disclosure provides products and methods that provide for the stability of functional amino acids in food matrices. In a general embodiment, the products include either a source of beta-glucans or a source of protein low in reducing sugars, in combination with a functional amino acid in a binder having low amounts of, or being substantially free of, reducing sugars. Methods for improving the stability of functional amino acids in food matrices are also provided. The products and methods of the present disclosure provide several advantages including, for example, the reduction or avoidance of degradation and browning of the products during processing and storage.

ENERGY-SUPPLEMENTING SACCHARIDE SOURCE AND ITS USES

Trehalose, prepared by the method containing a step of allowing a non-reducing saccharide-forming enzyme to act on a partial starch hydrolysate exhibiting a reducing power, is advantageously used as an energy-supplementing saccharide source and used in energy-supplementing compositions as an effective ingredient. The saccharide source and compositions can be suitably used as pharmaceutical compositions for supplementing energy for living bodies without a fear of causing side effects.

METHOD OF PRODUCING HIGHLY FUNCTIONAL SPORTS BEVERAGE

The present invention provides a method of producing a highly functional sports beverage, comprising: a first process of preparing a thick fermented milk, and preparing a naturally fermented vinegar; a second process of mixing 10-20 parts by weight of native honey per 100 parts by weight of the thick fermented milk to prepare a base mixture; a third process of mixing 80-100 parts by weight of baking soda per 100 parts by weight of the naturally fermented vinegar to prepare a functional mixture; a fourth process of mixing 5-20 parts by weight of the functional mixture per 100 parts by weight of the base mixture to form a beverage mixture; a fifth process of adding salt to the beverage mixture; and a sixth process of thermally sterilizing the beverage mixture mixed with the salt, and filling and packaging the same in container. According to the present invention, the highly functional sports beverage provides various functions including thirst relief, fatigue recovery, nutrition supply, metabolism ...

단백질이 풍부한 미세조류 바이오매스 미분 과립 및 이의 제조 방법

... 본 발명은 60 ㎛ 내지 300 ㎛의 Dmode 및 70 ㎛ 내지 420 ㎛의 D4,3을 갖는 COULTER174; 브랜드의 LS 레이저 과립측정기에서 측정된 입자 크기 분포; 0.60% 내지 0.70%의 HOSOKAWA 분말 특징 평가기에서 측정된 통기 밀도; 및 15% 내지 25%, 바람직하게는 18% 내지 21%의 HOSOKAWA 분말 특징 평가기에서 측정된 압축성을 갖는 것을 특징으로 하는, 단백질이 풍부한 미세조류 바이오매스 미분 과립에 관한 것이다.

METHOD FOR MANUFACTURING PANAX GINSENG AND ANGELICA GIGAS JELLY CONTAINING PURIFIED EXTRACT OF ACTIVE-FORM PANAX GINSENG AND ANGELICA GIGAS AS COMPOSITE MATERIALS

The present invention relates to a method for manufacturing a Panax ginseng and Angelica gigas jelly containing a purified extract of active-form Panax ginseng and Angelica gigas as composite materials, and more specifically, to a method for manufacturing a Panax ginseng and Angelica gigas jelly containing a purified extract of active-form Panax ginseng and Angelica gigas as composite materials, in which washed Panax is milled, decursin and decursinol angelate are extracted and purified using the active-form Panax ginseng containing active-form Panax ginseng active-form saponin and Korean native Angelica gigas by repeated heat treatment, solubilized Angelica gigas is mixed with purified Angelica gigas, and the two materials are mixed with saccharide and solubilized Gelidium amansii by heating to manufacture jellies. COPYRIGHT KIPO 2018 ...

COMPOSITION, DRINK, METHOD OF PRODUCTION AND USE THEREOF

A composition includes green coffee extract and yerba mate extract, and is suitable for mixing or infusing with a base liquid to obtain an edible drink with an energizing and stimulating effect. A drink is made with such a composition. 1. Composition comprising green coffee extract and yerba Mate extract , suitable for being mixed or infused with a basic liquid to obtain an edible drink.2. Composition according to further comprising Andean Maca extract.3. Composition according to claim 2 , wherein the Andean Maca extract is a dry aqueous extract.4. Composition according to claim 1 , wherein the yerba Mate extract is a dry extract of yerba Mate claim 1 , comprising at least 8% of xanthines.5. Composition according to any of the previous claims claim 1 , wherein the green coffee extract is a hydroalcoholic extract claim 1 , comprising at least 50% chlorogenic acid.6. Composition according to claim 1 , further comprising bay extract or peppermint extract and/or extract of roasted coffee.7Momordica grosvenori. Composition according to further comprising at least one sweetener chosen from the group comprising honey claim 1 , mixed flower honey claim 1 , and/or sucrose claim 1 , fructose claim 1 , dextrose claim 1 , maltose claim 1 , lactose claim 1 , fructose claim 1 , invert sugar claim 1 , polyols claim 1 , sorbitol claim 1 , sweeteners derived from Stevia claim 1 , sweeteners derived from claim 1 , sweeteners derived from mogrosides.8. Drink comprising a composition according to mixed or infused into an edible base liquid.9. Drink according to claim 8 , wherein the base liquid comprises at least water.10. Drink according to claim 8 , wherein the base liquid comprises at least one natural fruit juice.11. Drink according to claim 10 , wherein the natural juice is at least one chosen from natural lemon juice claim 10 , natural mandarin juice claim 10 , natural orange juice claim 10 , non-sanguine orange juice claim 10 , natural apple juice claim 10 , natural pomegranate ...

CHARACTERIZATION OF RICE

Processes for the production of a composition comprising material derived from seeds of plants of the genus Oryza, the process comprise the steps of: (a) providing material derived from seeds of the genus Oryza; and (b) determining the presence or absence and/or measuring the amount of at least one iminosugar in the material of step (a). Also described is the use of material derived from seeds of plants of the genus Oryza, which material comprises at least one iminosugar, as a food or feed supplement for lowering the glycaemic index (GI) value of said food or feed.

NUTRITIONAL SUPPLEMENTS

The present invention provides nutritional supplements comprising alginate, preferably in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms. 1. (canceled)2. A liquid nutritional supplement comprising;a) 0.1 to 2.0 wt % alginateb) 0.1 to 1.5 wt % pectin, andc) 35 to 80 wt % active ingredients, where the active ingredients are selected from one or more of the ingredients consisting of sugars, complex carbohydrates, electrolytes, and amino acids.3. (canceled)4. A liquid nutritional supplement comprising;a) 0.1 to 3.5 wt % alginate, andb) 35 to 80 wt % active ingredients, where the active ingredients are selected from one or more of the ingredients consisting of sugars, complex carbohydrates, electrolytes, and amino acids.5. The liquid nutritional supplement according to claim 4 , wherein the alginate content is 0.1 to 2.0 wt %.6. The liquid nutritional supplement according to claim 2 , wherein the alginate content is 0.3 to 0.7 wt %.7. The liquid nutritional supplement according to claim 2 , wherein the alginate is high-guluronate (high-G) alginate.8. The liquid nutritional supplement according to claim 2 , wherein the pectin content is 0.2 to 1.0 wt %.9. The liquid nutritional supplement according to claim 8 , wherein the pectin content is 0.2 to 0.6 wt %.10. The liquid nutritional supplement according to claim 9 , wherein the pectin content is 0.3 to 0.5 wt %.11. The liquid nutritional supplement according to claim 2 , wherein the pectin is high-ester/high-methylated (HE/HM) pectin.12. The liquid nutritional supplement according to claim 2 , wherein the content of active ingredients is 40 to 80 wt %.13. The liquid nutritional supplement according ...

Proteinriegel

Die vorliegende Erfindung betrifft einen Proteinriegel, der aus einer formbaren Masse gebildet ist, die Proteine und/oder Proteinhydrolysate enthält. Die formbare Masse enthält ein Kollagenhydrolysat mit einem mittleren Molekulargewicht von bis zu 1.700 Da als ein Proteinhydrolysat.

Compositions

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts.

Composition and use

The invention provides the simultaneous, separate or sequential feeding or administration of a carnitine substance (e.g. L-carnitine) with an agent for increasing the blood/plasma insulin concentration. The agent may be protein, carbohydrate or one or more amino acids or a combination of such nutrients. The co-administration or co-feeding of the carnitine substance and the agent provide for the reduction of whole body fat mass, particularly associated with excess dietary energy intake. The disclosed co-administration may also provide for the treatment of insulin resistance, fat oxidation disorders or obesity, and for increasing energy expenditure and fat metabolism. Compositions and kits containing the carnitine substance and the agent are provided, as are methods of treatment employing the co-administration or feeding of the carnitine substance and the agent. Also described is the upregulation of several genes in response to the treatments of the invention, including ACAT1, PNPLA2, PDK2 ...

Nutritional supplements

The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

NUTRITIONAL SUPPLEMENTS

The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms. 19-. (canceled)10. A method for providing carbohydrates to an athlete , comprising: (i) 0.2 to 16 wt % alginate,', '(ii) 0.12 to 12 wt % pectin, and', '(iii) 75 to 99 wt % active ingredients, where the active ingredients are selected from one or more of the ingredients consisting of sugars, complex carbohydrates, mineral salts, and amino acids; and, '(a) dissolving a solid composition in water to produce a sports drink, wherein the solid composition comprises(b) providing the sports drink to the athlete before, during and/or after exercise.11. The method according to claim 10 , wherein the alginate content of the composition is 0.2 to 4 wt %.12. The method according to claim 11 , wherein the alginate content of the composition is 0.2 to 2.0 wt %.13. The method according to claim 10 , wherein the pectin content of the composition is 0.12 to 2.4 wt %.14. The method according to wherein the pectin content of the composition is 0.12 to 1.4 wt %.15. The method according to claim 10 , wherein the composition comprises claim 10 ,a) 0.2 to 2 wt % alginate,b) 0.12 to 1.4 wt % pectin, andc) 75 to 99 wt % active ingredients, where the active ingredients are selected from one or more of the ingredients consisting of sugars, complex carbohydrates, mineral salts, and amino acids.16. The method according to claim 10 , wherein the alginate is high-guluronate (high-G) alginate.17. The method according to claim 10 , wherein the pectin is high-ester/high-methylated (HE/HM) pectin.18. The method according to claim 10 , wherein the sugars ...

Nutritional gel composition

COMPOSITION FOR SPORTS DRINKS

The present invention relates to a composition for sports drinks. More specifically, the composition for sports drinks contains L-arginine, L-carnitine, L-glutamine. According to the present invention, the use of the composition for sports drinks helps a user quickly recover from fatigue during workout and also promote exercise effect by increasing endurance. In addition, the composition for sports drinks can also allows the user to lose weight by accelerating break down of body fat. COPYRIGHT KIPO 2017 ...

uso de d-ribose para aperfeiçoar adaptação a tensão física

Edible energy composition

Method of increasing lean body mass

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

Use of D-ribose to enhance adaptation to physical stress

Methods of improving adaptation to physical stress by administering D-ribose and methods of administering D-ribose to improve adaptation to physical exercise.

Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source consisting of whey protein containing whey protein micelles and a source of casein. The inventive heat sterilized enteral composition preferably has a cysteine content of 1.2 to 2.4% by weight of the composition. The present invention is furthermore directed to a process for preparing a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein consisting of whey protein containing whey protein micelles and casein, which comprises the steps of: (i) Providing an aqueous solution of a protein source consisting of whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization treatment step; (iv) Performing a heat treatment step; (v) Optionally ...

Nutritional supplements

The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

영양 보충제

... 본 발명은 위즙의 낮은 pH에 노출될 경우 위에서 하이드로겔을 형성하는, 알긴산염과 펙틴을 조합하여 포함하는 영양 보충제를 제공한다. 하이드로겔의 형성은 위장 내 당 및 기타 활성 성분들의 방출을 지연시킨다. 영양 보충제는 원치 않는 위장 증상을 일으킴이 없이 당 및 복합 탄수화물을 고농도로 포함할 수 있다.

쌀의 특징화

... 본 발명은 벼 속 식물의 종자로부터 유래한 물질을 포함하는 조성물의 생산 방법으로서, 상기 방법은: (a) 벼 속 종자로부터 유래한 물질을 제공하는 단계; 및 (b) 단계 (a)의 물질에서 하나 이상의 이미노슈가의 존재 또는 부재를 결정하고/거나 단계 (a)의 물질에서 하나 이상의 이미노슈가의 양을 측정하는 단계를 포함한다. 또한 개시된 것은 벼 속 식물의 종자로부터 유래한 하나 이상의 이미노슈가를 포함하는 물질의 용도로서, 식품 또는 식사 보충제로서 상기 식품 또는 식사의 혈당 지수 (GI) 값을 낮추기 위한 것이다.

COMPOSITIONS

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts.

Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source comprising whey protein preferably containing whey protein micelles, and a source of casein, and optionally other proteins. The inventive heat sterilized enteral composition preferably has a cysteine content of at least 1.2% by weight of the protein source. The present invention is furthermore directed to a process for preparing such a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein comprising whey protein containing whey protein micelles and casein and optionally other proteins. The process comprises the steps of: (i) Providing an aqueous solution of a protein source comprising whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization ...

Heat sterilized high protein enteral compositions with whey protein which comprises whey protein micelles and a source of casein

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source consisting of whey protein containing whey protein micelles and a source of casein. The inventive heat sterilized enteral composition preferably has a cysteine content of 1.2 to 2.4% by weight of the composition. The present invention is furthermore directed to a process for preparing a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein consisting of whey protein containing whey protein micelles and casein, which comprises the steps of: (i) Providing an aqueous solution of a protein source consisting of whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization treatment step; (iv) Performing a heat treatment step; (v) Optionally ...

Composition containing protopanaxatriol and protopanaxadiol

A composition including: at least one mixture selected from the group consisting of a mixture of (A) panaxatriol and (B) protopanaxatriol and a mixture of (C) panaxadiol and (D) protopanaxadiol, wherein a ratio (A)/(B) of a mass of the (A) panaxatriol to a mass of the (B) protopanaxatriol is 1 or greater, and a ratio (C)/(D) of a mass of the (C) panaxadiol to a mass of the (D) protopanaxadiol is 1 or greater.

Low protein infant formula with increased essential amino acids

The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula.

Agent for improving lipid metabolism

This invention provides an effective means or method for improving lipid metabolism, and a means or method for treatment or prevention of diseases or disorders associated with the lipid metabolism disorder. Specifically, this invention relates to an agent for improving the lipid metabolism comprising, as active ingredients, broken cells of a lactic acid bacterium, and to a method for enhancing an effect of a lactic acid bacterium for improving the lipid metabolism comprising a step of breaking the lactic acid bacterium.

Use of pasteurized akkermansia for treating metabolic disorders

The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

HIGH-PROTEIN COMPOSITIONS AND METHODS OF THEIR MAKING AND USE

Disclosed here are methods to deliver protein to people in need of high protein. Also disclosed are methods to improve the protein content of comfort foods. Dehydrated meat powder or broth may be used to enhance the protein content of comfort foods. 1. A composition comprising a comfort food and a protein mix , wherein the composition has higher protein content than protein content of said comfort food , said protein mix contributing to said higher protein content of the composition.2. The composition of claim 1 , wherein proteins from the protein mix contribute to more than 50% of total protein content in said composition.3. The composition of claim 1 , wherein proteins from the protein mix contribute to more than 90% of total protein content in said composition.4. The composition of claim 1 , wherein the protein mix is prepared from a source selected from the group consisting of animal claim 1 , plant and insect.5. The composition of claim 1 , wherein the comfort food is selected from the group consisting of macaroni & cheese claim 1 , casserole claim 1 , mashed potato claim 1 , pot pie claim 1 , spaghetti sauce claim 1 , grilled cheese claim 1 , pasta claim 1 , noodle claim 1 , snack crisps claim 1 , chips claim 1 , soup claim 1 , chowder claim 1 , sauce claim 1 , grits claim 1 , cereals claim 1 , grain-creamed cereals claim 1 , bread claim 1 , battered dough claim 1 , snack mix claim 1 , gravy and combination thereof.6. The composition of claim 1 , wherein the composition is manufactured for commercial sale or commercial use.7. The composition of claim 1 , wherein the protein mix is prepared from poultry.8. The composition of claim 1 , wherein the protein mix is prepared from an organism selected from the group consisting of chicken claim 1 , turkey claim 1 , duck claim 1 , ostrich claim 1 , quail claim 1 , goose claim 1 , and combination thereof.9. The composition of claim 1 , wherein the composition comprises at least 5% (w/w) protein.10. The composition of ...

Fat-binding compositions

A fat-binding composition contains an inclusion complex with a host molecule and a guest molecule. The guest molecule includes one or more amino acids, vitamins, flavorants or related compounds, rutin, betanin, derivatives thereof, and mixtures thereof. The fat-binding composition may be in the form of a tablet or powder, for example, and may be incorporated into a food or beverage product. If in the form of a powder or tablet, the composition may optionally contain a carbonation-forming component and may be dissolved in carbonated or non-carbonated water. The fat-binding composition may also be employed in a method for binding fat ingested by an animal which includes having the animal ingest the composition, or a food or beverage product containing the same.

QUICK DROP AND DRINK NUTRITION AND MACHINE FOR MANUFACTURING THE SAME

A water soluble shell or binder is used to encapsulate nutrients, flavoring, other food grade ingredients or combinations thereof together as a single serving or unit. The unit or single serving may be distributed to people to provide nutrition to people in mass casualty situations. In this manner, more nutrients may be delivered since water which has a significant amount of weight and volume need not be transported to the people. Moreover, in normal situations, the water soluble shell or binder dissolves sufficiently quick so that the user can quickly consume nutrients. 1. A method of manufacturing a solid form having a binder and an ingestible food product for conveniently mixing the ingestible food product with drinkable water , the method comprising the steps of:providing the ingestible product as a plurality of granules or powder;providing an ingestible water dissolvable binder that is dissolvable in 80 degree Fahrenheit water in under 10 minutes when the ingestible water dissolvable binder is submersed under water and the water is still;mixing the ingestible water dissolvable binder and the powdered ingestible food product;filling a cavity of a die with the mixed ingestible water dissolvable binder and powdered ingestible food product;binding the powered ingestible food product into the solid form with the ingestible water dissolvable binder.2. The method of wherein a dimension of the cavity is so that a width of the solid form is smaller than a mouth of a container and a length of the solid form is shorter than a height of the container.3. The method of wherein the ingestible food product is sugar claim 1 , flavor claim 1 , protein or combinations thereof.4. The method of wherein the ingestible water dissolvable binder is cellulose based claim 1 , rice based.5. The method of wherein the ingestible water dissolvable binder is provided in a liquid form.6. The method of wherein the food product is a flavor claim 1 , sugar claim 1 , protein claim 1 , carbohydrate ...

ALCOHOLIC COMPOSITIONS HAVING A LOWERED RISK OF ACETALDEHYDEMIA

The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)17. The method according to claim 13 , wherein the deuterated alcohol has the formula CDCDOH.18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. (canceled)27. (canceled)28. (canceled)29. (canceled)30. (canceled)31. (canceled)32. (canceled)33. (canceled)34. The method of claim 13 , wherein from 1 to 40% by weight of the composition is ethanol.35. The method of claim 13 , wherein at least 15 mole percent of the ethanol is said deuterated alcohol.36. The method of claim 13 , wherein at least 30 mole percent of the ethanol is said deuterated alcohol.37. The method of claim 13 , wherein at least 50 mole percent of the ethanol is said deuterated alcohol.38. The method of claim 13 , wherein at least 75 mole percent of the ethanol is said deuterated alcohol.39. The method of claim 13 , wherein at least 95 mole percent of the ethanol is said deuterated alcohol.40. The method of claim 13 , wherein from 0.25 to 60% by weight of the composition is deuterated ethanol.41. The method of claim 13 , wherein the beverage claim 13 , further comprises: an additional component suitable for the alcoholic beverage.42. The method of claim 13 , wherein the beverage claim 13 , further comprises: a sweetener that is suitable for the alcoholic beverage.43. The method of claim 13 , wherein the beverage claim 13 , further comprises: an odorant that is suitable for the alcoholic beverage.44. The method of claim 13 , wherein the beverage claim 13 , further comprises: a flavorant that is suitable for the alcoholic beverage.45. The method of claim 13 , wherein the beverage claim 13 , further comprises: ...

COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance. 1. A method of inducing a physiological effect selected from the group consisting of alleviation of the symptoms of viral induced obesity , preventing viral induced obesity increasing lean body mass , decreasing body fat , increasing energy , increasing the feeling of well-being , alleviation of cold symptoms , and improving the skin tone , roughness and appearance in a subject comprising:providing a composition comprising effective amounts of a sulfated polysaccharide and a sialic acid,and orally administering said composition to said patient under conditions such that said physiological effect is induced.2. The method of claim 1 , wherein said symptom is obesity.3. The method of claim 1 , wherein said administration of said composition induces weight reduction in a subject.4. The method of claim 1 , wherein said administration of said composition increases the lean body mass of said subject.5. The method of claim 1 , wherein said administration of said composition reduces cellulite in said subject.6. The method of claim 1 , wherein said administration of said composition improves a skin parameter selected from the group consisting of improved skin tone claim 1 , improved skin tightness in said subject and improved skin roughness.7. The method of claim 1 , wherein said administration of said composition reduces body fat in said subject.8. The method of claim 1 , wherein said composition is a dietary supplement.9. The method of claim 1 , wherein said composition is a nutritional ...

SNACKING PRODUCT WITH CAPSAICIN OR ANALOGUE THEREOF

A zero-calorie to near-zero-calorie snacking product that, when consumed, provides a feeling of fullness prior to absorption of energy-providing food, i.e., pre-absorptive satiation is disclosed. The snacking product is based on the stimulation of vagal nerve endings in the gastro-intestinal tract by encapsulated capsaicin. The encapsulation of capsaicin avoids the burning sensation in the mouth which may be objectionable to some consumers. 130-. (canceled)31. A snacking product comprising: a flavor system that comprises encapsulated capsaicin , an encapsulated capsaicin analogue , or a combination thereof; wherein the snacking product is a zero-calorie to near-zero calorie snacking product; wherein the snacking product does not comprise capsiate; and wherein the flavor system further comprises food fibers.32. The snacking product of claim 31 , wherein the snacking product is configured to stimulate vagal nerve endings in a gastrointestinal tract.33. The snacking product of claim 32 , wherein the vagal nerve endings express the transient receptor potential cation channel subfamily receptor V member 1 (TRPV1) receptor.34. The snacking product of claim 32 , wherein the vagal nerve endings express the cholecystokinin (CCK) receptor.35. The snacking product of claim 31 , wherein the encapsulated capsaicin claim 31 , encapsulated capsaicin analogue claim 31 , or combination thereof is micro-encapsulated.36. The snacking product of claim 31 , wherein the flavor system further comprises Korean Pine Oil.37. The snacking product of claim 31 , wherein the snacking product is an energy drink claim 31 , an energy bar claim 31 , a dietary supplement claim 31 , a capsule claim 31 , a pill claim 31 , a lozenge claim 31 , a sub-combination thereof or a combination thereof.38. The snacking product of claim 31 , wherein the snacking product is located in a screw cap of a beverage container.39. The snacking product of claim 38 , wherein the snacking product is released upon opening of ...

Compositions with specific oligosaccharides to prevent later in life obesity or related comorbidities, by increasing colonic scfa production and/or by increasing glp-1 secretion

The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in reducing and/or avoiding excessive fat mass accumulation and/or in preventing any related later in life health disorders in an infant or a young child such as later in life obesity and related comorbidities, by increasing colonic SCFA production and/or GLP-1 secretion/releasein said infant or young child.

Use of Glycomacropeptide to Improve Women's Health

Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. GMP-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.

Use of lactobacillus plantarum composition for manufacturing anti-fatigue probiotic composition for improve exercise performance

The present invention is directed to a use of anti-fatigue probiotic bacteria for improving exercise performance, particularly the fatigue caused by exercise. The anti-fatigue probiotic bacteria increases muscle mass and endurance, decreases blood lactate, ammonia, and creatine kinase concentration, and changes body composition; the said bacteria can be used to improve exercise performance.

ORAL LIPID SUPPLEMENTS FOR TREATING PAIN AND FIBROMYALGIA

A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating systemic pain from fibromyalgia. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus. 2. The method of wherein an effective unit dose comprises at least about 1 g of the phospholipids.3. The method of wherein an effective daily dosage is 4 g of the phospholipids claim 2 , said daily dosage comprising four unit dosages delivered approximately every 6 hours over a 24-hour period.4. The method of wherein the daily dosage is delivered for about 14 days.5. The method of wherein the unit dosage also includes an amount of caffeine effective to reduce fatigue and enhance alertness and/or focus.6. The method of wherein an effective unit dose comprises at least 1.2 g of the phospholipids.7. The method of wherein an effective daily dosage is 4.8 g of the phospholipids claim 6 , said daily dosage comprising four unit dosages delivered approximately every 6 hours over a 24-hour period.8. The method of wherein the phospholipids comprises about 19-29% phosphatidylcholine (PC) claim 1 , 15-25% phosphatidylethanolamine (PE) claim 1 , 3.5%-10% phosphatidic acid (PA) claim 1 , 10-18% phosphatidylinositol (PI) claim 1 , 2-10% claim 1 , phosphatidylglycerol (PG) claim 1 , 10-20% glycolipids and phosphatidylserine (PS).10. The method of wherein an effective unit dose comprises about 1 g of the phospholipids and about 1 gm of caffeine.11. The method of wherein an effective unit dose comprises about 1 g of the phospholipids and about 1.75 gm of caffeine.12. The method of wherein an effective daily dosage is four 1 g dosages of the phospholipids and four 1 g dosages of caffeine claim 9 , said 1 g dosages delivered approximately every 6 hours in a 24-hour period.13. The method of wherein an effective daily dosage is at least about 4 g of the ...

ALCOHOLIC COMPOSITIONS HAVING A LOWERED RISK OF ACETALDEHYDEMIA

The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)22. The pharmaceutical composition of claim 18 , wherein at least 5 mole percent of the ethanol is a deuterated alcohol having the formula CDCDOH.23. The pharmaceutical composition of claim 18 , wherein at least 15 mole percent of the ethanol is said deuterated alcohol.24. The pharmaceutical composition of claim 23 , wherein at least 30 mole percent of the ethanol is said deuterated alcohol.25. The pharmaceutical composition of claim 24 , wherein at least 50 mole percent of the ethanol is said deuterated alcohol.26. The pharmaceutical composition of claim 25 , wherein at least 75 mole percent of the ethanol is said deuterated alcohol.27. The pharmaceutical composition of claim 26 , wherein at least 95 mole percent of the ethanol is said deuterated alcohol.28. (canceled)29. (canceled)30. (canceled)31. (canceled)32. (canceled)33. (canceled)34. The pharmaceutical composition of claim 18 , wherein from 1 to 40% by weight of the composition is ethanol.35. The pharmaceutical composition of claim 18 , wherein from 0.25 to 60% by weight of the composition is deuterated ethanol.36. The pharmaceutical composition of claim 18 , wherein from 50 to 100% by weight of the ethanol in the composition is deuterated ethanol.37. The pharmaceutical composition of claim 18 , further comprising: water.38. The pharmaceutical composition of claim 18 , further comprising: a pharmaceutically acceptable excipient.39. The pharmaceutical composition of claim 18 , further comprising: water and a pharmaceutically acceptable excipient. The present application claims priority benefit under 35 U.S. ...

DEUTERATED CAFFEINE AND USES THEREOF

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder. 1140-. (canceled)142. The nutritional supplement of claim 141 , wherein at least two to eight instances of Y are deuterium.143. The nutritional supplement of claim 141 , wherein nine or ten instances of Y are deuterium.147. The nutritional supplement of claim 141 , wherein the nutraceutically acceptable salt of the compound of Formula (I) is an HCl claim 141 , sulfate claim 141 , acetate claim 141 , phosphate claim 141 , diphosphate claim 141 , maleate claim 141 , citrate claim 141 , mesylate claim 141 , nitrate claim 141 , tartrate claim 141 , or gluconate salt.148. The nutritional supplement of claim 147 , wherein the salt is a citrate salt.151. The nutritional supplement of claim 141 , comprising about 1 mg to about 10 claim 141 ,000 mg of the compound of Formula (I) claim 141 , or a nutraceutically acceptable salt claim 141 , hydrate claim 141 , or solvate thereof.152. The nutritional supplement of claim 141 , comprising about 1 mg to about 1000 mg of the compound of Formula (I) claim 141 , or a nutraceutically acceptable salt claim 141 , hydrate claim 141 , or solvate thereof.153. The nutritional supplement of claim 141 , comprising about 1 mg/ml to about 100 mg/ml of the compound of Formula (I) claim 141 , or a nutraceutically acceptable salt claim 141 , hydrate claim 141 , or solvate thereof.154. The nutritional supplement of claim 141 , comprising about 10 mg/ml to ...

SWEET TASTE RECEPTOR ANTAGONIST COMPOSITIONS

The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject. 1. A composition comprising gymnemic acid and at least one form of zinc.225-. (canceled) This application is a continuation of U.S. application Ser. No. 15/423,212, filed Feb. 2, 2017, which is a continuation of U.S. application Ser. No. 15/194,411, filed Jun. 27, 2016, now issued as U.S. Pat. No. 9,585,905, which is a continuation of U.S. application Ser. No. 14/738,326, filed Jun. 12, 2015, now issued as U.S. Pat. No. 9,421,217, which claims priority, pursuant to 35 U.S.C. § 119(e), to U.S. Provisional Patent Application Ser. No. 62/011,096, filed Jun. 12, 2014, and U.S. Provisional Patent Application Ser. No. 62/025,725, filed Jul. 17, 2014, the contents of each of which are incorporated herein by reference in their entireties.The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject.Gymnemic acid is extracted from , a woody climbing plant native to India, Africa, and. China. Gymnemic acid is a dietary supplement sold worldwide, primarily in encapsulated forms. (See Ogawa et al., (2004) 45:8-18) Gymnemic acid is known to ...

ANTI-INTOXICATION COMPOSITION AND PROCESS

A process for making an anti-intoxication food supplement composition, said process comprising the steps of combining sulfuric acid with water, such that the volume ratio of sulfuric acid to distilled water lies in the range 1:1 to 1:5, and with a sulfate salt at a ratio of 10-40% volume, forming a first mixture, combining the first mixture in a vessel at a pressure above atmospheric pressure, allowing an exothermic reaction to heat up the mixture forming a reacted first mixture, cooling the reacted first mixture, adding a compound containing metal ions to the reacted first mixture, to form a second mixture, diluting the second mixture with water and adding at least one sweetener, flavoring agent, micro nutrient, macro nutrient, or food additive such as a vitamin to provide an anti-intoxication food supplement composition. 1. A process for making an anti-intoxication food supplement composition , said process comprising the steps of:a. combining a food grade acid with water, such that the volume ratio of food grade acid:distilled water lies in the range 1:1 to 1:5, and with a sulfate salt at a ratio of 10-40% volume, forming a first mixture;b. combining the first mixture in a vessel at a pressure above atmospheric pressure, allowing an exothermic reaction to heat up the mixture forming a reacted first mixture;c. cooling the reacted first mixture;d. adding a compound containing metal ions to the reacted first mixture, to form a second mixture;e. diluting the second mixture with water; andf. adding at least one sweetener, flavouring agent, micro nutrient, macro nutrient, or food additive such as a vitamin to provide an anti-intoxication food supplement composition.2. The process according to claim 1 , wherein the sulfate salt in step a. is ammonium sulfate.3. The process according to claim 1 , wherein the food grade acid is of approximately 90 to 99.99 percent purity.4. The process according to claim 1 , wherein the volume ratio of sulfuric acid:distilled water lies ...

Non-Processed Protein-based Nutritional Edible Substance

A non-processed protein-based nutritional edible substance for providing protein to a consumer. The non-processed protein-based nutritional edible substance includes a quantity of sunflower seeds, a quantity of pumpkin seeds, and a quantity of sweet binding compound. The sunflower seeds and the pumpkin seeds are the primary source for protein and beneficial nutrients. The quantity of sunflower seeds, the quantity of pumpkin seeds, and the quantity of sweet binding compound is heterogeneously mixed into a nutritional mixture, which allows the non-processed protein-based nutritional edible substance to be easily consumed by a person. The nutritional mixture can include additional quantities of ingredients to enhance the flavor, nutrients, protein quantity of the non-processed protein-based nutritional edible substance and/or to provide a recreational/medicinal effect to the consumer. 1. A non-processed protein-based nutritional edible substance comprises:a quantity of sunflower seeds;a quantity of pumpkin seeds;a quantity of sweet binding compound; andthe quantity of sunflower seeds, the quantity of pumpkin seeds, and the quantity of sweet binding compound being heterogeneously mixed into a nutritional mixture.2. The non-processed protein-based nutritional edible substance as claimed in comprises:the quantity of sunflower seeds being a first percent volume (vol %) of the nutritional mixture;the quantity of pumpkin seeds being a second vol % of the nutritional mixture; andthe first vol % being equal to the second vol %.3. The non-processed protein-based nutritional edible substance as claimed in claim 2 , wherein the first vol % and the second vol % ranging between 60 to 90 vol % of the nutritional mixture.4. The non-processed protein-based nutritional edible substance as claimed in comprises:the quantity of sweet binding compound ranging between 0.1 to 10 vol % of the nutritional mixture.5. The non-processed protein-based nutritional edible substance as claimed in ...

PROBIOTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED CONDITIONS

The present invention provides a method and composition for ameliorating or reducing the symptoms and signs and for the treatment of obesity, diabetes, and related conditions in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition comprising a mixture of probiotic microorganisms with distinct but complementary pathways of carbohydrate metabolism, for a time sufficient to ameliorate, reduce or treat at least one sign or symptom of obesity, diabetes or cardiovascular disease. Compositions having the desired properties, and methods for their use in pharmaceutical and nutritional formulations, are provided. 1LactobacillusBifidobacteriumLeuconostoc,. A composition for preventing or ameliorating obesity or an obesity-related condition; said composition containing , as an active ingredient , at least two species of probiotic microorganisms , wherein the first species is selected from the group comprising and the second species is selected from the group comprising or in a capsule , tablet , dry powder , food or beverage.2L. acidophilus, L. rhamnosus, B. bifidumB. lactis;Leuconostoc mesenteroides.. A composition for preventing or ameliorating obesity or an obesity-related condition; said composition containing , per capsule or serving , at least 1.5 billion each of and and at least 1 billion CFU of3. The composition according to wherein the obesity-related condition is selected from the group comprising hyperglycemia claim 1 , insulin resistance claim 1 , diabetes claim 1 , hypertriglyceridemia claim 1 , hypercholesterolemia claim 1 , atherosclerosis claim 1 , angina pectoris claim 1 , myocardial infarction and/or stroke.4Lactobacillus, Bifidobacterium, Streptococcus, Saccharomyces,Leuconostoc.. The composition according to comprising three or more probiotic microorganisms selected from the group consisting of and5Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus ...

KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION

Compositions and methods for producing elevated blood levels of ketone bodies and modifying metabolic function in a mammal. Compositions include at least one ester of S-beta-hydroxybutyrate and/or a mono- or di-ester of S-1,3-butanediol and at least one ketone body component. The ketone body component includes beta-hydroxybutyrate, acetoacetate, or both. The beta-hydroxybutyrate is R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, or both. When the ketone body component is S-beta-hydroxybutyrate, the 1,3-butanediol is R-1,3-butanediol, S-1,3-butanediol, or both. Compositions may comprise a keto stack of multiple forms of ketone bodies.

Ketogenic diet compatible fenfluramine formulation

A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.

AGENT FOR INCREASING INTESTINAL BUTYRIC ACID AND PROLIFERATION AGENT FOR BUTYRIC ACID-PRODUCING BACTERIA

[Problem] 18-.9. A method for proliferating butyric acid-producing bacteria , comprising the step of adding 1-kestose to a medium containing butyric acid-producing bacteria to culture the butyric acid-producing bacteria.10. A method for treatment or prevention of intestinal inflammation , fatty liver , diabetes , colorectal cancer , or obesity , comprising the step of increasing the amount or the concentration of butyric acid or the number of butyric acid-producing bacteria in intestines in a human or an animal having or being at risk of having intestinal inflammation , fatty liver , diabetes , colorectal cancer , or obesity by letting take the human or the animal 1-kestose.11. A method for producing a pharmaceutical preparation or a health food for treatment or prevention of intestinal inflammation , fatty liver , diabetes , colorectal cancer , or obesity using 1-kestose. The present invention relates to an agent for increasing intestinal butyric acid, a food composition for increasing intestinal butyric acid, a proliferation agent for butyric acid-producing bacteria, a food composition for proliferating butyric acid-producing bacteria, a method for increasing intestinal butyric acid, a method for proliferating butyric acid-producing bacteria, and a method for treatment or prevention of intestinal inflammation, fatty liver, diabetes, colorectal cancer, or obesity and use of 1-kestose for producing a pharmaceutical preparation for treatment or prevention of these diseases.Butyric acid is a short chain fatty acid and produced by butyric acid-producing bacteria that reside in the intestines in human and animal bodies. Studies in recent years have reported that butyric acid has various physiological effects such as anti-inflammatory effects and colorectal cancer preventing effects and that butyric acid may prevent or ameliorate various diseases.Based on theses, attempts to use butyric acid have been made for prevention and treatment of diseases and health promotion. ...

METHOD AND APPARATUS FOR MODIFYING BEHAVIOR OF A USER VIA A NETWORK

A method and apparatus for modifying a behavior of a user are disclosed. For example, the method determines a baseline of a behavior to be modified for a user, the baseline comprising at least one triggering event that is established for the behavior to be modified and at least one action to be taken when the at least one triggering event is detected, detects the at least one triggering event that is established for the behavior to be modified for the user, identifies the at least one action to be performed when the at least one triggering event is detected, and performs the at least action that is identified. 1. A method comprising:determining, via a processor of an application server of a communications network operated by a network service provider, a baseline of a behavior to be modified for a user, the baseline comprising at least one triggering event that is established for the behavior to be modified and at least one action to be taken when the at least one triggering event is detected, wherein the baseline of the behavior is determined in accordance with a profile of the user, wherein the profile of the user comprises: a listing of at least one positive behavior for the user, a listing of at least one negative behavior for the user, and a listing of one or more actions to be taken in accordance with the listing of the at least one positive behavior for the user and the listing of the at least one negative behavior for the user, wherein the at least one action is at least one of the one or more actions, wherein the behavior is a way in which the user conducts himself;detecting, via the processor, the at least one triggering event that is established for the behavior to be modified for the user based on data received from a sensor via the communications network;identifying, via the processor, the at least one action to be performed when the at least one triggering event is detected; andperforming, via the processor through the communications network, the at ...

USE OF SAFFRON AND/OR SAFRANAL AND/OR CROCIN AND/OR PICROCROCIN AND/OR DERIVATIVES THEREOF AS A SATIATION AGENT FOR THE TREATMENT OF OBESITY

Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight. 18-. (canceled)9. An oral formulation for treating an overweight or obese subject , comprising:a composition containing a saffron stigmata solvent extract including a combination of picrocrocin, safranal, and crocin, wherein said saffron stigmata solvent extract is obtained by:a) isolating saffron stigmata; andb) extracting the isolated saffron stigmata with a solvent, and wherein the saffron stigmata solvent extract is present in an amount which is effective for reducing fat-body mass while keeping lean-body mass and muscular mass stable;wherein the oral formulation is in a form selected from the group consisting of a tablet, a film-coated tablet, an effervescent tablet, a lozenge, and a capsule.10. The oral formulation according to claim 9 , wherein the oral formulation is in a form selected from the group consisting of a tablet claim 9 , a film-coated tablet claim 9 , and an effervescent tablet.11. The oral formulation according to claim 9 , wherein the oral formulation further comprises at least one pharmaceutically and/or dietetically acceptable excipient in the composition.12. The oral formulation according to claim 9 , wherein the oral formulation comprises a dose of the saffron stigmata solvent extract in an amount ranging from 60 mg to 150 mg.13. The oral formulation according to claim 9 , wherein the oral formulation comprises the saffron stigmata extract in an amount of between 0.01 and 50% claim 9 , relative to the total weight of the dosage form.14. The oral formulation according to claim 13 , wherein the oral formulation comprises the saffron stigmata extract in an amount of between 0.05 and 20% claim 13 , relative to the total weight of the dosage form.15. The oral formulation according to claim 14 , wherein the oral formulation comprises ...

BEER COMPOSITION AND METHOD OF MAKING SAME

A beer composition including a hydration additive is described. The hydration additive includes a coconut extract and a salt additive. The beer composition may provide a hydrating effect or a feeling of hydration upon consumption. The coconut extract may be in the form of a frozen coconut concentrate that can be diluted with water to form a coconut solution. The coconut solution may be added during the brewing process together with the salt additive in a mixture or may be added separately or sequentially. Typically, the salt additive is in the form of sodium chloride and may contain other optional salts. 1: A beer composition comprising a hydration additive , the hydration additive comprising:a coconut extract; anda salt additive.2: The beer composition of claim 1 , wherein the coconut extract is a frozen coconut concentrate.3: The beer composition of claim 1 , wherein the coconut extract is diluted with water to form a coconut solution.4: The beer composition of claim 3 , wherein the coconut extract is diluted to from about 50% to about 100% of the concentration of a natural coconut water to form the coconut solution.5: The beer composition of claim 1 , wherein the salt additive comprises sodium.6: The beer composition of claim 5 , wherein the salt additive further comprises potassium claim 5 , calcium claim 5 , magnesium claim 5 , or a combination thereof.7: The beer composition of claim 1 , wherein the salt additive is added in an amount to bring a total sodium content of the beer composition to an amount of about 4-5% of a daily recommended intake value per 12 ounces.8: The beer composition of claim 1 , wherein the salt additive is added in an amount to bring a total sodium content of the beer composition to an amount of from about 110 mg to about 115 mg per 12 ounces.9: The beer composition of claim 3 , wherein the coconut solution is present in an amount of from 1 to 15% v/v.10: The beer composition of claim 3 , wherein the coconut solution is present in an ...

BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS

AH1362 (NCIMB 41715) produces a polysaccharide and increases energy excretion. The strain is used in the prevention or treatment of obesity and obesity-related metabolic syndrome. 125-. (canceled)26Bifidobacterium longum. A strain of AH1362 deposited with the NCIMB under accession number NCIMB 41715.27. The strain as claimed in in the form of viable cells or in the form of non-viable cells.28Bifidobacterium longum. A formulation comprising a strain of AH1362 deposited with the NCIMB under accession number NCIMB 41715.29. The formulation as claimed in which further comprises a probiotic material.30. The formulation as claimed in which further comprises a prebiotic material.31. The formulation as claimed in which further comprises an ingestible carrier.32. The formulation as claimed in wherein the ingestible carrier comprises a pharmaceutically acceptable carrier chosen from a capsule claim 31 , a tablet claim 31 , or a powder.33. The formulation as claimed in wherein the ingestible carrier comprises a food product chosen from acidified milk claim 31 , yoghurt claim 31 , frozen yoghurt claim 31 , milk powder claim 31 , milk concentrate claim 31 , cheese spreads claim 31 , dressings claim 31 , or beverages.34. The formulation as claimed in which further comprises at least one of a protein or a peptide rich in glutamine/glutamate claim 31 , a lipid claim 31 , a carbohydrate claim 31 , a vitamin claim 31 , a mineral claim 31 , a trace element claim 31 , or a combination thereof.35. The formulation as claimed in wherein the strain is present in an amount of more than 10cfu per gram of the formulation.36. The formulation as claimed in which further comprises an adjuvant.37. The formulation as claimed in which further comprises a bacterial component.38. The formulation as claimed in which further comprises a drug entity.39. The formulation as claimed in which further comprises a biological compound.40Bifidobacterium longum. A freeze-dried composition comprising the strain ...

COMPOSITIONS AND METHODS FOR KETO STACKING WITH BETA-HYDROXYBUTYRATE AND ACETOACETATE

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and/or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters. 1. A composition for administering ketone bodies to a subject , comprising:one or more beta-hydroxybutyrate salts;one or more acetoacetate salts;beta-hydroxybutyrate free acid; andoptionally acetoacetate free acid.2. The composition of claim 1 , wherein the composition comprises:about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts; andabout 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid.3. The composition of claim 1 , wherein the composition comprises:about 55% to about 95% by combined weight of the one or more beta-hydroxybutyrate salts and the beta-hydroxybutyrate free acid; andabout 5% to about 45% by total weight of the one or more acetoacetate salts and optionally the acetoacetate free acid.4. The composition of claim 1 , wherein the one or more beta-hydroxybutyrate salts are selected from the group consisting of sodium beta-hydroxybutyrate claim 1 , potassium beta-hydroxybutyrate claim 1 , magnesium beta-hydroxybutyrate claim 1 , calcium beta-hydroxybutyrate claim 1 , and amino acid beta-hydroxybutyrate.5. The composition of claim 1 , wherein the one or more acetoacetate salts are selected from the group consisting of ...

Improved enrichment methods for preparing tannic acid compositions

Improved enrichment methods for preparing tannic acid compositions that have superior potency in inhibiting D-amino acid oxidase, and superior purity and safety profiles. The tannic acid compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) can be used for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

Natural sweetener compositions

The invention provides improved natural sweetener compositions comprising certain isolated compounds and their derivatives. The present invention also includes ingestible compositions comprising the present compounds and methods of sweetening the sweet taste of consumable materials.

FOOD PRODUCT HAVING HIGH MILK PROTEIN CONTENT AND PROCESS OF MAKING SAME

A food product and process of making the same is provided which results in a high milk protein product having 10% to 25% milk protein content, higher phospholipids compared to unadulterated cow milk, a casein to whey ration of at least 50:50 and is shelf stable for at least six months. In the process whole milk and at least one milk protein source is mixed, heated and contacted with an acid or acidulating substance and co-precipitated to produce a semi-solid precipitate. The precipitate is mixed with starch and cooked. 1. A food product having high milk protein content comprising ,a) at least 10% milk protein by dry weight;b) higher phospholipids compared to unadulterated cow milk; andc) starch;wherein said food product has a casein to whey ratio of at least 50:50, and is shelf stable for at least six months.2. The food product of wherein said product has a shelf life of at least one year.3. The food product of wherein said product has 20% more phospholipids than said unadulterated cow milk.4. The food product of claim 1 , wherein said product has 10% to 25% milk protein content by dry weight claim 1 , said milk protein comprising protein of whole milk and buttermilk.5. A food product made by the process of:a) mixing whole milk and at least one milk protein source to form a mixture;b) heating said mixture to a temperature of 195° F. to 212° F.;c) contacting said mixture with an acid or acidulating substance and co-precipitating said whole milk and said milk protein source to produce a semi-solid precipitate;d) combining said semi-solid precipitate with starch to form a dough-like mixture; ande) cooking said mixture to produce a food product having at least 10% milk protein content by dry weight.6. A method of producing a food product having high milk protein content claim 1 , the method comprising claim 1 ,a) mixing whole milk and at least one milk protein source to form a mixture;b) heating said mixture to a temperature of 195° F. to 212° F. prior to or at the same ...

Nutritional supplements

The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

Bifidobacteria for reducing food, energy and/or fat intake

This invention relates to the use of a bacterium of the genus Bifidobacterium , particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and/or fat intake.

Compositions comprising bacterial strains

Provided are compositions comprising a bacterial strain of the genus Blautia , for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.

Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function

Compositions and methods for producing elevated blood levels of ketone bodies and modifying metabolic function in a mammal. Compositions include at least one ester of S-beta-hydroxybutyrate and/or a mono- or di-ester of S-1,3-butanediol and at least one ketone body component. The ketone body component includes beta-hydroxybutyrate, acetoacetate, or both. The beta-hydroxybutyrate is R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, or both. When the ketone body component is S-beta-hydroxybutyrate, the 1,3-butanediol is R-1,3-butanediol, S-1,3-butanediol, or both. Compositions may comprise a keto stack of multiple forms of ketone bodies.

COMPOSITIONS

The present invention relates to the use of a fruit extract and optionally other specific nutrients for preventing, reducing or minimising exercise-induced systemic inflammation and/or for promoting recovery from intense exercise. The invention also relates to compositions comprising such fruit extracts. 122-. (canceled)23. A composition comprising: consists of components having a molecular weight of less than 1000; and', '(ii) contains one or more of a nucleoside; a glycosylated phenolic acid or a phenolic ester, or a glycosylated flavonoid;, '(a) a water-soluble extract of tomato fruit, wherein the extract(b) an exogenous source of dietary nitrate or a precursor of endogenous nitric oxide selected from citrulline, glutamine or arginine and wherein the exogenous source comprises a water-based extract of fresh fruit or vegetable tissue, wherein the fruit or vegetable contains levels of nitrate sufficiently high to result in final extract concentrations of 7.5 g/l nitrate or greater; and(c) folic acid or a metabolite of folic acid selected from 5-methoxytetrahydrofolate or tetrahydrofolate.24. The composition according to wherein the source of dietary nitrate (b) is selected from a water-soluble extract from Swiss chard claim 23 , rocket claim 23 , spinach claim 23 , rhubarb claim 23 , strawberry and lettuce.25. The composition according to in the form of a pharmaceutical product claim 23 , nutraceutical product claim 23 , drink claim 23 , food substance or food supplement.26. The composition according to formulated as a gel claim 23 , powder claim 23 , food bar or dispersable tablet.27. A dosage form comprising the composition of comprising between 25 mg and 250 mg of nitrate.28. The dosage form according to comprising between 10 mg and 500 mg of folic acid.29. A method of treating claim 27 , reducing claim 27 , minimising or preventing exercise-induced systemic inflammation in a subject claim 27 , comprising: [ (i) consists of components having a molecular weight ...

FUNCTIONALLY REINFORCED DESALTED NUTRITIONAL COMPOSITIONS FROM HALOPHYTES AND PREPARATION METHOD THEREOF

Disclosed are a functionally reinforced desalted nutritional composition, a desalted extract and a cold-water-extracted salt substitute, which are derived from halophytes that grow in coastal regions under highly saline conditions and thus retain high salt concentrations, as well as the use of the desalted nutritional composition for combating obesity. More particularly, this invention relates to a functionally reinforced desalted nutritional composition, a desalted extract and a salt substitute cold-water-extracted from halophytes that inhabit extreme environments of high salinity under high salt stress, the halophytes being desalted through a cold water extraction process at a low temperature based on the difference in water solubility of salts with change in temperature to allow only sodium chloride to be selectively removed, and the composition thus having decreased sodium content as well as having increased content of useful minerals such as potassium, as well as nutrients and physiologically active substances, which are naturally contained in halophytes. 1. A method of preparing a functionally reinforced desalted nutritional composition from a halophyte , comprising the steps of:(a) mixing dried powder of the halophyte with water at 9° C. or lower and stirring a resultant mixture;(b) centrifuging the stirred mixture and removing a supernatant having a high salt content to recover a desalted precipitate; and(c) drying the desalted precipitate.2. A functionally reinforced nutritional composition from a halophyte , comprising sodium of less than 6.8 wt % and carbohydrates of 61 wt % or greater , based on a dry weight.3. The functionally reinforced nutritional composition from the halophyte as set forth in claim 2 , comprising potassium (K) of 0.1 to 3.0 wt % claim 2 , calcium (Ca) of 0.1 to 2.0 wt % and magnesium (Mg) of 0.1 to 1.5 wt % claim 2 , based on the dry weight.4. The functionally reinforced nutritional composition from the halophyte as set forth in ...

MICROBIOME-BASED DIAGNOSIS, PREDICTION AND TREATMENT OF RELAPSING OBESITY

A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain. 1. A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program , the method comprising determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject , wherein the amount of said at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of said at least one microbe is retained at said level following said weight loss program , wherein the amount or presence of said at least one microbe or product thereof is predictive of weight regain.2. A method of monitoring the efficacy of a dieting aid in a subject:(a) treating the subject with a dieting aid; and{'i': Lactobacillus', 'Bacteroides', 'Bacteroides acidifaciens', 'Bacteroides uniformis, '(b) analyzing for the presence or the level of a microbe in the family Weeksellaceae and/or product thereof, a microbe in the family Tissierellaceae and/or a product thereof, a microbe in the genus and/or a product thereof, a microbe in the genus and/or a product thereof, a microbe in the class Mollicutes and/or a product thereof, a microbe in the class Gammaproteobacteria and/or a product thereof, a microbe in the phylum Actinobacteria ...

HAFNIA ALVEI BASED PHARMACEUTICAL AND FOOD COMPOSITIONS FOR INDUCING SATIATION AND PROLONGING SATIETY

The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei. 1Hafnia alvei.. A method of stimulating weight loss in a subject in need thereof , the method comprising administering to the subject an effective amount of2Hafnia alvei. method according to claim 1 , wherein administering an effective amount of prolongs satiety in the subject in need thereof.3Hafnia alvei. The method according to claim 1 , wherein administering an effective amount of reduces the meal size in the subject in need thereof.4Hafnia alvei. The method according to claim 1 , wherein administering an effective amount of reduces food intake in the subject in need thereof.5Hafnia alvei. The method according to claim 1 , wherein administering an effective amount of reduces weight gain in the subject in need thereof.6. (canceled)7. The method according to claim 1 , wherein the subject is not obese.8. The method according to claim 1 , wherein the subject is obese.9Hafnia alvei. The method according to claim 1 , wherein is administered to the subject in the form of a pharmaceutical composition.10Hafnia alvei. The method according to claim 1 , wherein is administered to the subject in the form of a food composition.11. The method according to claim 10 , wherein the food composition is selected from the group comprising a complete food composition claim 10 , a food supplement claim 10 , and a nutraceutical composition.12Hafnia alvei. The method according to claim 1 , wherein is a probiotic.13Hafnia alvei. The method according to claim 1 , wherein is inactivated.14. The method according to claim 10 , wherein the food composition comprises at least one prebiotic.15. The method according to claim 14 , wherein at least one prebiotic comprises a ...

DIETARY SUPPLEMENT DERIVED FROM THE SENEGALIA PLANT

A dietary supplement is provided whereby the daily administration of materials derived from the plants is provided orally to humans for the purpose of producing or maintaining weight loss as well as improving a person's physical performance and increasing the person's lean muscle mass. The materials include these portions of the plant that are normally considered waste or inedible, such as leaves, bark, and roots. The materials contain at least one of the alkaloids from the group consisting of N-methyl-β-phenethylamine; N,N-dimethylphenethylamine; and N-methyl-β-methylphenethylamine. The materials can be administered in their natural form or as extracts, and can be administered in various ways including powders, liquids, capsules and tablets. The material may also be used as a tea. For weight loss and weight control, the materials may also be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered for the purpose of increasing muscle mass concurrently with a high protein diet as well as an exercise program. More particularly, the present invention relates to the discovery that useful and exploitable levels of these adrenergic amines occur in the plant species of 1. A method for promoting energy and weight loss while stimulating thermogenesis and suppressing appetite which comprises administering to a human a composition comprising:{'i': 'Senegalia Berlandieri', "about 0.025 milligrams to about 2.5 milligrams per 1 kilogram of said human's body weight of an extract of one of the group consisting of , or a pharmaceutically acceptable salt thereof."}2. The method of claim 1 , where said composition is in an oral dosage form.3. The method of claim 2 , wherein said oral dosage form is selected from the group consisting of a chewable tablet claim 2 , a quick dissolve tablet claim 2 , an effervescent tablet claim 2 , a hard gelatin capsule claim 2 , a soft gelatin capsule claim 2 , a powder claim 2 ...

Fat Composition

A fat composition comprises: from 10% to 30% by weight of diglycerides; and from 70% to 90% by weight of triglycerides, wherein the triglycerides comprise from 40% to 75% by weight of CN50 triglycerides and from 15% to 40% by weight of CN52 triglycerides; based on total triglycerides present in the composition; and wherein the fat composition has from 55 to 85 solid fat content at 10° C.; and from 35 to 70 solid fat content at 20° C.; and from 5 to 25 solid fat content at 30° C.; and from 0 to 10 solid fat content at 40° C.; measured on 20° C. stabilized fat according to ISO 8292-1.

CONCENTRATED LIQUID DIET

The concentrated liquid diet disclosed is a concentrated liquid diet having a total amount of a medium-chain fatty acid having 8 carbon atoms and a medium-chain fatty acid having 10 carbon atoms included as constitutive fatty acids of a triglyceride being 2.5 to 8.0 g per 100 kcal of the energy of the concentrated liquid diet, the concentrated liquid diet having in the total mass of the medium-chain fatty acid having 8 carbon atoms and the medium-chain fatty acid having 10 carbon atoms the rate of the medium-chain fatty acid having 10 carbon atoms being no less than 60% by mass, and the rate of the medium-chain fatty acid having 8 carbon atoms being no greater than 40% by mass. 1. (canceled)3. The method of claim 2 , wherein the medium-chain fatty acids of the triglycerides having 10 carbon atoms are 75% to 95% of the total mass of the medium-chain fatty acids in the concentrated liquid diet; and the medium-chain fatty acids of the triglycerides having 8 carbon atoms are 5% to 25% of the total mass of the medium-chain fatty acids in the concentrated liquid diet.4. The method of claim 2 , wherein the concentrated liquid diet comprises the triglyceride in an amount of 2.6 to 10 g per 100 kcal of the energy of the concentrated liquid diet.5. The method of claim 2 , wherein the concentrated liquid diet is administered in the form of a soup claim 2 , enteral formula or parenteral formula.6. The method of claim 2 , wherein the concentrated liquid diet further comprises an oil selected from the group consisting of soybean oil claim 2 , rapeseed oil claim 2 , sesame oil claim 2 , palm oil claim 2 , palm kernel oil claim 2 , coconut oil claim 2 , and fish oil claim 2 , or any combination thereof.7. The method of claim 2 , wherein the concentrated liquid diet comprises one or more components selected from the group consisting of nutritional vitamins claim 2 , nutritional minerals claim 2 , emulsifying agents claim 2 , milk proteins claim 2 , soybean proteins claim 2 , and ...

DRY EXPANDED FOOD PRODUCT MADE FROM PROTEIN, AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to a dry expanded food product comprising the following essential ingredients: a food-grade protein concentrate of animal or plant origin, and residual water. The expansion can be obtained during a step of treatment in a microwave device. 1. Dry expanded food product only comprising , as structural ingredients , ingredients of the group constituted of a food-grade protein concentrate of animal or plant origin , and residual water.2. Dry expanded food product comprising at least the following essential ingredients:a food-grade protein concentrate of animal or plant origin, andresidual water.3. Food product according to also comprising cheese.4. Food product according to claim 3 , which comprises at least one cheese from the group comprising refined cheese claim 3 , non-refined cheese claim 3 , melted cheese and powdered cheese.5. Food product according to claim 1 , comprising 35% to 97% by weight of protein.6. Food product according to claim 1 , comprising at least one aromatic claim 1 , nutritional and/or aesthetic auxiliary additive.7. Food product according to claim 6 , comprising as a nutritional auxiliary additive claim 6 , food fibres.8. Dry expanded food product according to claim 1 , wherein the food-grade animal protein concentrate is a milk protein concentrate.9. Food product according to claim 2 , only comprising as structural ingredients claim 2 , ingredients from the group constituted of a food-grade protein concentrate of animal or plant origin claim 2 , cheese claim 2 , and residual water.10. Food product according to claim 2 , also comprising as a structural ingredient claim 2 , added food-grade fat.11. Food product according to claim 2 , only comprising as structural ingredients claim 2 , ingredients from the group constituted of a food-grade protein concentrate of animal or plant origin claim 2 , cheese claim 2 , a food-grade fat and residual water.12. Food product according to claim 2 , also comprising as a structural ...

Fermented infant formula

A fermented infant formula or follow on formula for promoting a growth trajectory more similar to the growth trajectory in breast-fed infants. A fermented infant formula or follow on formula for i) promoting a balanced growth trajectory or body development in an infant and/or ii) preventing or reducing the risk of an unbalanced growth trajectory or body development in an infant. Saud formula comprises 3 to 7 g lipid/100 kcal, 1.25 to 5 g protein/100 kcal and 6 to 18 g digestible carbohydrate/100 kcal and wherein the nutritional composition comprises an ingredient fermented by lactic acid producing bacteria, and 0.05 to 1.5 wt % lactic acid based on dry weight.

HEAT STERILIZED HIGH PROTEIN ENTERAL COMPOSITIONS WITH WHEY PROTEIN WHICH COMPRISES WHEY PROTEIN MICELLES AND A SOURCE OF CASEIN

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source consisting of whey protein containing whey protein micelles and a source of casein. The inventive heat sterilized enteral composition preferably has a cysteine content of 1.2 to 2.4% by weight of the composition. The present invention is furthermore directed to a process for preparing a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein consisting of whey protein containing whey protein micelles and casein, which comprises the steps of: (i) Providing an aqueous solution of a protein source consisting of whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization treatment step; (iv) Performing a heat treatment step; (v) Optionally performing a homogenization treatment step. Finally, the invention concerns the use of a protein source consisting of whey protein containing whey protein micelles and a source of casein, for preparing an enteral composition and/or for controlling the viscosity of a liquid enteral composition, wherein the enteral composition comprises 12 to 20 weight % total protein. The invention also concerns medical uses and treatments applying or using the inventive heat sterilized enteral composition. 1. A liquid heat sterilized enteral composition comprising:a protein source in an amount of 12 to 20% by weight of the composition;the protein source consisting of whey protein, containing whey protein micelles, and a source of casein; andwherein the heat sterilized enteral composition contains cysteine in an amount of 1.2 to 2.4% by weight of the protein source.2. The enteral composition according to claim 1 , wherein whey protein is present in an amount of 4.5 to 9% by weight of the composition.3. ...

HEAT STERILIZED HIGH PROTEIN ENTERAL COMPOSITIONS WITH WHEY PROTEIN WHICH COMPRISES WHEY PROTEIN MICELLES AND A SOURCE OF CASEIN

The present invention is directed to a liquid heat sterilized enteral composition comprising: a protein source in an amount of 12 to 20% by weight of the composition, the protein source comprising whey protein preferably containing whey protein micelles, and a source of casein, and optionally other proteins. The inventive heat sterilized enteral composition preferably has a cysteine content of at least 1.2% by weight of the protein source. The present invention is furthermore directed to a process for preparing such a heat sterilized enteral composition comprising protein in an amount of 12 to 20% by weight based on the weight of the composition, said protein comprising whey protein containing whey protein micelles and casein and optionally other proteins. The process comprises the steps of: (i) Providing an aqueous solution of a protein source comprising whey protein containing whey protein micelles and (ii) Adding a protein source containing casein; (iii) Optionally performing a homogenization treatment step; (iv) Performing a heat treatment step; (v) Optionally performing a homogenization treatment step. Finally, the invention concerns the use of a protein source comprising whey protein containing whey protein micelles, a source of casein and optionally other proteins, for preparing an enteral composition and/or for controlling the viscosity of a liquid enteral composition, wherein the enteral composition comprises 12 to 20 weight % total protein. The invention also concerns medical uses and treatments applying or using the inventive heat sterilized enteral composition. 1. A liquid heat sterilized enteral composition comprising:a protein source in an amount of 12 to 20% by weight of the composition,the protein source comprising whey protein, containing whey protein micelles, and a source of casein; andwherein the heat sterilized enteral composition contains cysteine in an amount of at least 1.2% by weight of the protein source.2. The enteral composition according ...

Composition for Relieving Hangovers

Provided is a composition for relieving a hangover including as its active ingredients Fisher nut extract, Steud. stem extract and fruit extract. It is verified the composition for relieving a hangover according to the present disclosure reduces blood alcohol concentration more significantly than the composition for relieving a hangover including as its active ingredients Steud. extract and extract as disclosed in Korean Patent Registration No. 181168 in in vivo tests (including animal testing and human experiment) and that has effects of considerably alleviating various hangover symptoms. 1. A composition for relieving a hangover including as its active ingredients:{'i': 'Corylus heterophylla', 'Fisher nut extract;'}{'i': 'Alnus japonica', 'Steud. stem extract; and'}{'i': 'Sorbus commixta', 'fruit extract,'}{'i': Corylus heterophylla', 'Alnus japonica', 'Sorbus commixta, 'wherein, for 100 wt % of the active ingredients, 50 to 70 wt % of the Fisher nut extract, 10 to 20 wt % of the Steud. stem extract and 10 to 30 wt % of the fruit extract are comprised.'}2. A health functional food including:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the composition for relieving a hangover of ; and'}a sitologically acceptable food material and a food additive,wherein, for the entire weight of the health functional food save for mixing water, 0.1 to 99.9 wt % of the composition for relieving a hangover are comprised.3. The health functional food of claim 2 , wherein the health functional food is a beverage. The present disclosure relates to a composition for relieving a hangover, more particularly a composition for relieving a hangover including as its active ingredients Fisher nut extract, Steud. stem extract and fruit extract.In drinking, a small dose of the whole alcohol is primarily absorbed through the esophageal mucosa and the oral mucosa. After that, about 90% of it is absorbed in the stomach and then 10% of it is absorbed in the small intestine. Alcohol thus ...

BETA-HYDROXYBUTYRIC ACID COMPOSITIONSAND METHODS FOR ORAL DELIVERY OF KETONE BODIES

Beta-hydroxybutyric acid compositions for oral delivery are substantially free of beta-hydroxybutyrate salts and are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By excluding beta-hydroxybutyrate salts (e.g., less than 1% by weight) containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be enriched with the R- or the S-enantiomer, a racemic mixture, pure R-beta-hydroxybutyric acid, or pure S-beta-hydroxybutyric acid. 1. An aqueous beta-hydroxybutyric acid composition for oral delivery to increase blood ketone level in a subject , comprising:water; andbeta-hydroxybutyric acid,wherein the composition is free or substantially free of beta-hydroxybutyrate salts so as to contain less than 1% of beta-hydroxybutyrate salts by combined weight of the beta-hydroxybutyric acid and any beta-hydroxybutyrate salts.2. The aqueous beta-hydroxybutyric acid composition of claim 1 , wherein the composition is a dilute solution in which the beta-hydroxybutyric acid has a concentration of about 0.4% w/v to about 6% w/v.3. The aqueous beta-hydroxybutyric acid composition of claim 2 , wherein the beta-hydroxybutyric acid has a concentration of about 0.6% w/v to about 5.5% w/v claim 2 , or about 0.9% w/v to about 5% w/v claim 2 , or about 1.2% w/v to about 4.5% w/v claim 2 , or about 1.5% w/v to about 4% w/v.4. The aqueous beta- ...

LOW PROTEIN INFANT FORMULA WITH INCREASED ESSENTIAL AMINO ACIDS

The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula. 1. A nutritional composition comprising protein , digestible carbohydrates and fat , wherein the protein comprises amino acids leucine , isoleucine and valine in a weight ratio leucine:isoleucine:valine is between (1.1-1.5):(0.9-1.1):1.0.2. The nutritional composition according to wherein the weight ratio leucine:isoleucine:valine is between (1.3-1.5):(0.9-1.1):1.0.3. The nutritional composition according to claim 1 , wherein the sum of leucine claim 1 , isoleucine and valine provides at least 20 wt % of the total amino acid content.4. The nutritional composition according to claim 1 , wherein the protein comprises between 120 and 180 mg leucine per 100 kcal in the total composition claim 1 , between 90 and 180 mg isoleucine per 100 kcal in the total composition claim 1 , and between 90 and 180 mg valine per 100 kcal in the total composition.5. The nutritional composition according to claim 4 , wherein the protein comprises between 130 and 160 mg leucine per 100 kcal in the total composition claim 4 , between 100 and 120 mg isoleucine per 100 kcal in the total composition and between 105 and 121 mg valine per 100 kcal in the total composition.6. The nutritional composition according to claim 1 , wherein the protein is present between 5 and 8% based on total calories of the composition.7. The nutritional composition according to claim 1 , further comprising at least one bifidogenic dietary fiber selected from the group consisting of beta-linked galaco-oligosaccharides claim 1 , transgalacto-oligosaccharides claim 1 , galacto-oligosaccharides claim 1 , lacto-N-tetraose (LNT) claim 1 , lacto-N-neotetraose (neo-LNT) claim 1 , fucosyl-lactose claim 1 , fucosylated LNT claim 1 , fucosylated neo-LNT claim 1 , and xylooligosaccharides.8. The nutritional composition according to claim 1 , further comprising at least one PUFA ...

Allulose-containing composition for promoting excretion of vegetable lipids from the body

The present application relates to an allulose-containing composition for promoting excretion of vegetable lipids from the body and a food comprising the composition of the present application and vegetable lipids.

Hops-based substance and use of the substance

The invention relates to a hops-based substance which comprises a mixture of (a) xanthohumol with the formula (1) and (b) at least one isomerized hops acid, preferably iso-alpha acid, in each case in a concentrated or isolated form. It has surprisingly been shown that a substance in which xanthohumol and iso-alpha acid are present in combination and in which each substance is present in a concentrated or isolated form in the combination substantially increases the effectiveness in conjunction with the prevention and/or control of liver diseases or liver damage when compared to xanthohumol alone. The inflammation- and fibrosis-inhibiting effect of xanthohumol and the inhibition of the fatty changes of liver cells is thus surprisingly increased by the presence of iso-alpha acid.

Ketogenic Dietary Consumable

A ketogenic dietary consumable provides optimal fats to a consumer who is on the ketogenic diet. The ketogenic dietary consumable utilizes both medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs) in order to provide necessary calories and avoid stomach discomfort and gastrointestinal distress associated with less triglyceride-diverse dietary supplements. The ketogenic dietary consumable includes a quantity of fractionated coconut oil, a quantity of avocado oil, and a quantity of macadamia nut oil. The quantity of fractionated coconut oil provides the ketogenic dietary consumable with valuable MCTs, which are easily digestible. The quantity of avocado oil and the quantity of macadamia nut oil supply the ketogenic dietary consumable with a strong source of LCTs, thus preventing the rapid digestion of the MCTs from the quantity of fractionated coconut oil that results in stomach discomfort.

PECTINS IMPROVING ENERGY REDISTRIBUTION IN ANIMALS

A composition includes a carbohydrate, which is pectin with an esterification degree less than 65%. A feed can include the composition. The composition or feed can be used for improving the feed intake pattern in animals and non-human animals or for improving the leanness of meat and other derived animal products. 1. A composition comprising a carbohydrate , whereby said carbohydrate comprises at least one pectin with an esterification degree less than 65%.2. The composition according to claim 1 , characterized in that said pectin has a degree of esterification less than 55%.3. The composition according to claim 1 , wherein the said pectin comprises one or more polymers of α-D-(1→4) galacturonic acid or mixtures of one or more of said polymers.4. The composition according to claim 1 , wherein the said composition further comprises vitamins claim 1 , trace elements claim 1 , minerals or carboxylic acids and/or salts thereof claim 1 , selected from the group of valeric acid claim 1 , formic acid claim 1 , acetic acid claim 1 , propionic acid claim 1 , medium chain fatty acids claim 1 , lactic acid claim 1 , butyric acid claim 1 , citric acid claim 1 , maleic acid claim 1 , fumaric acid claim 1 , benzoic acid claim 1 , succinic acid claim 1 , sorbic acid claim 1 , tartaric acid.5. The composition according to claim 1 , wherein the said pectin is present in said composition in concentration of between 1 to 100% of total weight of said composition.6. A feed comprising a composition according to and additional nutritive components.7. The feed according to claim 6 , wherein the said composition is present in 0.01 to 10% of the total amount of weight of said composition.8. The feed according to claim 6 , comprising 0.01 to 5% wt pectins based on the total weight of the feed formulation.9. A method for improving the feed intake pattern of a human or a non-human animal in order to repartition energy in the human or non-human animal claim 1 , comprising feeding the human or ...

METHOD FOR TREATING FATTY LIVER

A method of treating fatty liver comprising administering an effective amount of a plant belonging to a genus to a patient in need of the treatment. 1Cirsium. A method of treating fatty liver comprising administering an effective amount of a plant belonging to a genus to a patient in need of the treatment.2CirsiumCirsium brevicaule. The method of wherein the plant belonging to the genus is A. Gray.3CirsiumCirsium. The method of wherein the plant belonging to a genus is in form of an extract which is obtained by extracting the plant belonging to a genus with a solvent.4Cirsium. The method of wherein the plant belonging to a genus is in form of powder. This application is a divisional of U.S. patent application Ser. No. 14/911,835, which entered U.S. national phase on Feb. 12, 2016 from international patent application No. PCT/JP2014/071397, which was filed on Aug. 13, 2014, which claimed priority from Japan Patent Application No. 2013-168404 filed on Aug. 13, 2013, the entire content of which is herein incorporated as reference.The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 17, 2016, is named 14F079-PCT_Revised SEQUENCE LISTING.txt and is 7,297 bytes in size.The present disclosure relates to a method for treating fatty liver.Thistles are plants belonging to the genus of the family Asteraceae, and are distributed over wide areas from mountainous districts to seabeaches. In the world, there are 250 species or more of thistles, which are widely distributed over the Northern Hemisphere. Very wide local variations occur in the thistles. It is considered that there are 100 species or more of thistles in Japan, in which a new species of thistles may be currently discovered. In addition, there are also interspecific hybrids, and therefore, it is considered that taxonomy of the thistles may be difficult.It has been made clear ...

NUTRITIONAL COMPOSITIONS AND METHODS OF USING SAME

Described are compositions that can be used for medical purposes such as weight loss, obesity, diabetes control and the like. Methods of using these compositions are also described. 1. A nutritional composition including:less than about 35 g of net carbohydrate;at least 10 mg of fiber; andabout 1.0 g to about 2.5 g of protein per kilogram of an individual's body weight and that individual's height,wherein the nutritional composition comprises at least five intakes per day.2. The nutritional composition of claim 1 , wherein the nutritional composition is in a liquid dosage form claim 1 , in a solid dosage form claim 1 , in a powder dosage form claim 1 , or in a combination of forms.3. The nutritional composition of including about 100 g to about 200 g of net carbohydrate per day.4. The nutritional composition of further including about 2 claim 1 ,000 mg to about 12 claim 1 ,000 mg of omega 3 per day.5. The nutritional composition of further including an omega 6.6. The nutritional composition of claim 5 , wherein the ratio of omega 3 to omega 6 is about 1:1.7. The nutritional composition of further including at least one amino acid selected from phenylalanine claim 1 , valine claim 1 , threonine claim 1 , tryptophan claim 1 , methionine claim 1 , leucine claim 1 , isoleucine claim 1 , lysine and histidine.8. The nutritional composition of including all amino acids humans cannot synthesize.9. The nutritional composition of including at least about 15 g of fiber per day.10. The nutritional composition of including from about 10 g to about 50 g of fiber per day.11. The nutritional composition of further including less than about 150 mg of cholesterol per day.12. The nutritional composition of claim 1 , wherein the nutritional composition further comprises a component selected from the group consisting of vitamins claim 1 , minerals claim 1 , essential amino acids claim 1 , or a combination thereof.13. The nutritional composition of claim 1 , wherein the nutritional ...

BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS

This invention relates to new uses of (particularly, although not exclusively, probiotic ), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure. 1Bifidobacterium. A method of treating myocardial infarction in a mammal , the method comprising administering to a mammal in need of such treatment a bacterium of the genus or a mixture thereof.2Bifidobacterium. A method of treating congestive heart failure in a mammal , the method comprising administering to a mammal in need of such treatment a bacterium of the genus or a mixture thereof.3. The method of claim 1 , wherein the mammal in need of the treatment ingests a high-fat diet.4BifidobacteriumBifidobacterium. The method of claim 1 , wherein the is a probiotic or a mixture thereof.5Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis,Bifidobacterium angulatum,. The method of claim 1 , wherein the bacterium is of the species selected from the group consisting of and and mixtures of any thereof.6Bifidobacterium animalis.. The method of claim 5 , wherein the bacterium is of the species7Bifidobacterium animalislactis.. The method of claim 6 , wherein the bacterium is of the species subsp.8Bifidobacterium animalislactis. The method of claim 7 , wherein the bacterium of the species subsp. strain 420 (B420).9Lactobacillus.. The method of claim 1 , additionally comprising administering a bacterium of the genus10Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus sakei ...

KETOGENIC NUTRITIONAL COMPOSITION AND PREPARATION METHOD THEREOF

The present disclosure relates to nutritional composition in powder form capable of being used as an adjunct to a ketogenic diet program. The disclosed ketogenic nutritional composition can produce elevated and sustained levels of ketone bodies in blood and can synergistically induce nutritional ketosis in a subject. The ketogenic nutritional composition disclosed herein can exhibit improved physical stability, solubility, homogeneity and aqueous dispersibility as compared to existing ketogenic diet supplements, and is substantially free of carbohydrates. Further the disclosed ketogenic nutritional composition can contribute to reduction in body fat mass in individuals who are trying to lose weight, and can provide long-lasting energy and improved athletic performance to individuals during strenuous exercise. In an aspect, the present disclosure provides a ketogenic nutritional composition in powder form for promoting nutritional ketosis in a subject in need thereof, wherein the composition can include a fat, protein, vitamin, and phospholipids. 1. A ketogenic nutritional composition for promoting nutritional ketosis in a subject in need thereof , the composition comprising: fat , protein , vitamin , and phospholipids.2. The nutritional composition as claimed in claim 1 , wherein the fat is selected from the group consisting of coconut oil claim 1 , fractionated coconut oil claim 1 , medium chain triglyceride (MCT) oil and a mixture thereof.3. The nutritional composition as claimed in claim 1 , wherein the fat comprises coconut oil.4. The nutritional composition as claimed in claim 1 , wherein the protein comprises a natural protein selected from the group consisting of casein claim 1 , whey protein claim 1 , egg protein claim 1 , soy protein and a mixture of milk proteins.5. The nutritional composition as claimed in claim 4 , wherein the natural protein is casein claim 4 , and wherein the casein comprises sodium caseinate.6. The nutritional composition as claimed ...

Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) assosiated with intermittent fasting

The present invention provides a composition comprising HMB and methods of using HMB to mitigate loss of lean body mass, increase fat free mass, improve muscular performance, increase body fat loss and decrease body fat percentage in individuals undergoing intermittent fasting.

ISONITRAMINE COMPOUND AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING METABOLIC DISEASES

Provided are a pharmaceutical composition for preventing or treating metabolic diseases and a health food for alleviating metabolic diseases, each of which the pharmaceutical composition and the health food includes, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers, wherein such a compound exhibits effects of inhibiting fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus can be favorably utilized in the treatment of metabolic diseases, such as obesity, diabetes, and hyperlipidemia. 2. The method of claim 1 , wherein the metabolic disease is selected from the group consisting of obesity claim 1 , diabetes claim 1 , hyperlipidemia claim 1 , hypertriglyceridemia claim 1 , liver disease claim 1 , arteriosclerosis claim 1 , stroke claim 1 , myocardial infarction claim 1 , cardiovascular disease claim 1 , hyperglycemia claim 1 , insulin resistance claim 1 , and hyperinsulinemia. This application is a Continuation Application of U.S. patent application Ser. No. 15/752,592 filed on Apr. 26, 2018 under 35 U.S.C. § 120, which is the 35 U.S.C. § 371 national stage of International application PCT/KR2016/009036 filed on Aug. 17, 2016, which claims priority to Korean applications 10-2015-0115504 filed on Aug. 17, 2015 and 10-2016-0104145 filed on Aug. 17, 2016, respectively.The present invention relates to a composition for preventing or treating a metabolic disease, the composition including a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers.As the standard of living improves with the development of the economy, the number of modern people who belong to obesity, which is the main cause of metabolic diseases, is rapidly increasing. In particular, it is recently reported that one third of Americans and 20% of children are obese patients in the ...

PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APPETITE, CONTAINING N2-(M-TRIFLUOROBENZYL), N6-(P-NITROBENZYL)PURINE (TNP) OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

The present invention relates to a pharmaceutical composition containing TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) or a pharmaceutically acceptable salt thereof as an active ingredient for suppressing appetite. Particularly, TNP or a pharmaceutically acceptable salt thereof can be effectively used as an active ingredient of a pharmaceutical composition or a nutraceutical food for suppressing appetite since it is confirmed that food intake is reduced and weight gain is inhibited in mice when the central nervous system of mice is treated with TNP. 2. The method for suppressing appetite according to claim 1 , wherein the TNP compound is characterized by reducing food intake.48.-. (canceled herein) The present invention relates to a pharmaceutical composition or a nutraceutical food for suppressing appetite containing TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) or a pharmaceutically acceptable salt thereof as an active ingredient.TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) is a commercially available chemical that is an inositol hexakisphosphate kinase specific inhibitor (Padmanabhan et al., J. Biol. Chem. 2009). According to previous reports, TNP inhibits the biosynthesis of 5-inositol pyrophosphate, thereby lowering the level of intracellular 5-inositol polyphosphate and increasing the insulin signaling response of hepatocytes (Chakraborty et al., Cell, 2010. 143(6):897-910). When TNP is treated to stem cells, it can inhibit aging of the cells (Zhang et al., Stem Cell Res Ther. 2014).There is no effective treatment method for obesity which is defined as excessive fat in the body, yet. However, the world-wide obesity population continues to increase. The world-wide obesity incidence became almost double from 1980 to 2008. In fact, it is known that about 11% of the world's population [total: about 500 million people (male: 200 million, female: 300 million)] is obesity patients (BMI 30 kg/mor more) and this trend is growing very rapidly ...

BIFIDOBACTERIA FOR REDUCING FOOD, ENERGY AND/OR FAT INTAKE

This invention relates to the use of a bacterium of the genus , particularly, but not exclusively, a bacterium of the ssp. strain 420 (B420) for use in reducing food, energy and/or fat intake. 111-. (canceled)12Bifidobacterium. A method for reducing food , energy and/or fat intake comprising administering to a mammal a bacterium of the genus or a mixture thereof , wherein:{'i': 'Bifidobacterium', 'the administration of the bacterium of the genus reduces the food, energy and/or fat intake in the mammal; and'}{'i': Bifidobacterium', 'Bifidobacterium animalis', 'lactis, 'the bacterium of the genus comprises ssp. strain 420 (B420).'}1314-. (canceled)15. The method according to claim 12 , wherein the bacterium is used in combination with one or more fibres and/or prebiotics.16. The method according to claim 15 , wherein the one or more fibres and/or prebiotic comprise(s) polydextrose.17. A method according to claim 12 , wherein the bacterium is administered to the mammal in the form of a food product claim 12 , a dietary supplement or a pharmaceutically acceptable formulation.18. (canceled)19. The method according to claim 17 , wherein the bacterium is used in combination with one or more fibres and/or prebiotics.20. The method according to claim 19 , wherein the one or more fibres and/or prebiotic comprise(s) polydextrose.21. The method according to claim 17 , wherein the bacterium is administered to the mammal in the form of a medical food product.22. The method according to claim 21 , wherein the bacterium is used in combination with one or more fibres and/or prebiotics.23. The method according to claim 22 , wherein the one or more fibres and/or prebiotic comprise(s) polydextrose.24. The method according to claim 17 , wherein the bacterium is administered to the mammal in the form of a medicament.25. The method according to claim 24 , wherein the bacterium is used in combination with one or more fibres and/or prebiotics.26. The method according to claim 25 , wherein ...

COMPOSITIONS COMPRISING GLUCOSE AND HEMICELLULOSE AND THEIR USE

Provided herein are purified hemicellulose compositions, sweetener compositions including purified hemicellulose compositions, as well as methods for making the same. Also provided are uses of the compositions. 130.-. (canceled)31. A hemicellulose composition comprising:about 82% to about 92% by dry weight of xylan;about 8% to about 9% by dry weight of xylo-oligosaccharide; andabout 4% to about 5% by dry weight of xylose.32. The hemicellulose composition of claim 31 , wherein the hemicellulose composition comprises about 87% to about 88% by dry weight of xylan.33. The hemicellulose composition of claim 31 , wherein the hemicellulose composition has a molecular weight (M) of less than 4000 Da.34. The hemicellulose composition of claim 31 , wherein the hemicellulose composition has a polyphenol content of less than about 0.5% by dry weight.35. The hemicellulose composition of claim 31 , wherein the hemicellulose composition has an antioxidant level of less than about 10000 μmol TE/100 g.36. The hemicellulose composition of claim 31 , wherein the hemicellulose composition has a purity of at least 95%.37. The hemicellulose composition of claim 31 , wherein the xylan comprises about 90% to about 99% by dry weight of arabinoxylan.38. A food product comprising the hemicellulose composition of . This application is a divisional application of U.S. Ser. No. 16/409,335, filed May 10, 2019, which claims the benefit of U.S. Provisional Application Ser. No. 62/669,684, filed May 10, 2018. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.The present description relates to compositions comprising glucose and hemicellulose and to their use, particularly as a food ingredient or as sweeteners or additives for orally consumed products.Additives and sweeteners are used in the production of foods and beverages and in other items for ingestion such as pharmaceuticals and supplements. Many sweeteners ...

EDIBLE ENERGY COMPOSITION WITH LOW CAFFEINE

An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like. 1. An edible energy composition comprising:caffeine in an amount less than 0.00045 g/ml;a choline derivative in an amount from about 0.0004 g/ml to about 0.009 g/ml; andat least one flavorant.2. The energy composition of wherein the caffeine is present in an amount from about 0.00008 g/ml to about 0.004 g/ml.3. The energy composition of wherein the caffeine is present in an amount from about 0.0001 g/ml to about 0.0003 g/ml.4. The energy composition of wherein the choline derivative is present in an amount from about 0.0008 g/ml to about 0.007 g/ml.5. The energy composition of wherein the choline derivative is present in an amount from about 0.001 g/ml to about 0.005 g/ml.6. The energy composition of wherein the choline derivative comprises citicoline.7. The energy composition of further comprising at least one amino acid or amino acid derivative.8. The energy composition of wherein the amino acids or amino acid derivatives are present in an amount from about 0.005 to about 0.05 g/ml.9. The energy composition of wherein the amino acids comprise a component selected from the group consisting of N-acetyl L-tyrosine claim 7 , L-phenylalanine claim 7 , taurine claim 7 , and combinations thereof.10. The energy composition of further comprising N-acetyl L-tyrosine in an amount from about 0.001 to about 0.01 g/ml.12. The energy composition of further comprising L-phenylalanine in an amount from about 0.001 to about 0.008 g/ml.13. The energy composition of further comprising taurine in an amount from about 0.002 to about 0.016 g/ml.14. The energy composition of further comprising vitamins in an amount from about 0.0003 g/ml to about 0.01 g/ml.15. The energy composition of further comprising a vitamin ...

CHEWY CONFECTION WITH REDUCED SUGAR

Low cariogenic and low-laxation chewy confections comprising a non-cariogenic sweetener comprising erythritol and a doctoring agent comprising at least one of sucromalt, linear inulin, branched inulin, brown rice syrup, indigestible dextrin, polydextrose, isomaltooligosaccharide, and soluble corn fiber are provided. Methods for preparing low cariogenic and low-laxation chewy confections are also provided. 1. A chewy confection composition comprising:(a) a non-cariogenic sweetener comprising erythritol;(b) a doctoring agent comprising at least one of sucromalt, linear inulin, branched inulin, brown rice syrup, reduced sugar glucose syrup, indigestible dextrin, polydextrose, isomaltooligosaccharide, and soluble corn fiber;(c) fat; and(d) a gelling agent,wherein a solids weight ratio of doctoring agent to erythritol is from about 1.3:1 to about 2.5:1.2. The chewy confection composition of wherein the solids weight ratio of doctoring agent to erythritol is from about 1.5:1 to about 2.2:1.3. The chewy confection composition of comprising from about 70 wt. % to about 97 wt. % solids.4. The chewy confection composition of comprising from about 75 wt. % to about 90 wt. % doctoring agent and non-cariogenic sweetener solids.5. (canceled)6. The chewy confection composition of wherein the non-cariogenic sweetener consists essentially of erythritol.7. (canceled)8. The chewy confection composition of wherein the doctoring agent consists essentially of sucromalt.9. The chewy confection composition of wherein the gelling agent comprises starch.10. The chewy confection composition of wherein the gelling agent further comprises gelatin and dextrin.11. The chewy confection composition of wherein the gelling agent comprises gelatin and gum Arabic.12. The chewy confection composition of comprising from about 2 wt. % to about 6 wt. % solids gelling agent.13. The chewy confection composition of comprising about 3 wt. % solids gelling agent.14. The chewy confection composition of ...

MICROBIOME-BASED DIAGNOSIS, PREDICTION AND TREATMENT OF RELAPSING OBESITY

A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain. 1. A method of reducing the risk of weight gain in a subject comprising administering to the subject a fecal transplant of a healthy , donor subject who has not undergone a weight loss program , wherein said donor subject has a BMI between 18.5-24.9 , wherein the subject has completed a weight loss program and reached a target weight , thereby reducing weight gain in the subject.2. The method of claim 1 , further comprising administering to the subject a flavonoid.3. The method of claim 2 , wherein said flavonoid is apigenin and/or naringenin.4. The method of claim 1 , further comprising administering to the subject a probiotic.5. The method of claim 4 , wherein said probiotic is a bacterial population associated with nitrate synthesis or heptose biosynthesis.6. The method of claim 1 , further comprising administering to the subject an antibiotic.7. The method of claim 6 , wherein said antibiotic agent downregulates an amount and/or activity of the class Mollicutes or of the order Bacteroidales.8. The method of claim 1 , further comprising analyzing said signature of said gut microbiome of the subject prior to the administering. This application is a division of U.S. patent application Ser. No. 16/077,751 filed on Aug. 14, 2018, which is a National Phase of PCT Patent Application No. PCT/IL2017/050187 ...

Nutritional formula

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

Synergistic Sweetening Compositions

A sweetening composition comprising sucralose and a purified extract of stevia. 1. A synergistic sweetening composition consisting of:sucralose, anda purified extract of stevia,wherein the weight ratio of sucralose to purified extract of stevia is 30:70; and the purified stevia extract comprises: rebaudioside A ranging from about 60% to about 100%.2. The synergistic sweetening composition of claim 1 , wherein the composition demonstrates about 27% synergy as compared to a sucralose control.3. The synergistic sweetening composition of claim 1 , wherein the purified stevia extract comprises rebaudioside A ranging from about 60% to about 95%.4. The synergistic sweetening composition of claim 1 , wherein the purified stevia extract comprises rebaudioside A ranging from about 70% to about 90%.5. The synergistic sweetening composition of claim 1 , wherein the purified stevia extract comprises about 90% rebaudioside A.6. The synergistic sweetening composition of having sweetness contribution ratio of sucralose and the purified stevia extract is about 90:10 to about 10:90.7. The synergistic sweetening composition of claim 1 , prepared by methods selected from the group consisting of dry blending claim 1 , spray drying claim 1 , agglomeration claim 1 , wet granulation claim 1 , compaction claim 1 , co-crystallization or the like.8. A synergistic sweetening composition consisting of:sucralose, anda purified extract of stevia,wherein the weight ratio of sucralose to purified extract of stevia is 30:70; and the purified stevia extract comprises less than about 40% rebaudioside-dulcoside blends.9. The synergistic sweetening composition of claim 8 , wherein the composition demonstrates about 25% synergy as compared to a sucralose control.10. The synergistic sweetening composition of claim 8 , prepared by methods selected from the group consisting of dry blending claim 8 , spray drying claim 8 , agglomeration claim 8 , wet granulation claim 8 , compaction claim 8 , co- ...

Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise

A weight loss system is presented herein. In one embodiment, the weight loss system that accelerates weight loss in a subject eating a caloric restricted diet with a minimum daily protein intake of about 3 oz. and engaging in daily physical activity equivalent to about 5,000 steps per day is presented. The weight loss system can comprise an effective amount of: an antimicrobial component that includes berberine, cinnamon and curcumin; fish oil; a probiotic component that includes Lactobacillus spp., Bifidobacterium spp., and Streptococcus spp.; an antioxidant, phytochemical component that includes apple extract, grape extract, green tea extract, and olive extract; and a vitamin component that includes vitamins A, B, C, D, and E. The weight loss system can stimulate a weight loss of at least 3% more than if not administered to the subject. Further presented herein is a method of facilitating weight loss in a subject and a method of improving the health of a subject participating in a weight loss program.

Methods and Materials for Increasing Lean Muscle Mass

A composition containing cinnamon extract is provided to increase lean muscle mass in a subject. Also described is a method of increasing lean muscle mass in a subject through the administration of the cinnamon extract. In some aspects, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months. 1. A composition for reducing a risk factor associated with Syndrome X in a subject , comprising:a water or water/ethanol extract of cinnamon bark, wherein the water or water/ethanol extract of cinnamon bark comprises at least 1 weight percent polyphenol type-A polymers,{'i': Cinnamomum', 'Cinnamomum, 'wherein said concentration of said polyphenol type-A polymers in said water or water/ethanol extract is obtained by preparing said water or water/ethanol extract by extraction of sp. in water by a process comprising heating said sp. and said water to about 100 degrees Celsius for 15 to 20 minutes, and subsequently reducing the temperature to about 80-95 degrees Celsius for 20-30 minutes.'}2. The composition of claim 1 , wherein said polyphenol type-A polymers are present at from 1 to 25 weight percent.3. A method for increasing lean muscle mass in a subject in need thereof comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to a subject in need thereof a therapeutically effective amount of the composition of .'}4. The method of claim 3 , wherein said subject has an abnormal body mass index.5. The method of claim 3 , wherein the therapeutically effective amount of the extract of cinnamon bark is administered orally claim 3 , intravenously claim 3 , by intramuscular injection claim 3 , by intraperitoneal injection claim 3 , or transdermally.6. The method of claim 3 , wherein the therapeutically effective amount of the extract of cinnamon bark is administered orally in the form selected from the group consisting of tablets claim 3 , suppositories claim 3 , pills claim 3 , ...

Novel lactobacillus sakei and composition comprising the same

The present disclosure relates to a novel Lactobacillus sakei strain and a composition comprising the same.

Ketogenic diet compatible fenfluramine formulation

A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.

Deuterated caffeine and uses thereof

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

Composition For Controlling Weight By Modulating Levels Of Peptides Involved In Fullness And/Or Appetite

The present invention provides compositions which comprise an extract with at least 5% in weight of anthocyanins and an extract with at least 15% in weight of phenylpropanoids which are specially indicated for their use in weight reduction periods because they reduce appetite and increase satiety though digestive tract-secreted hormones level modification. In a parallel and complementary way, these compositions act on the lipid metabolism of the adipose tissue cells by activating AMPK sensors and the fat oxidative and elimination pathways. Said composition is obtained by hydro-alcoholic extraction of Rosella flowers and Lemon Verbena leafs, using in the case of Lemon Verbena alcohol concentrations (ethanol, methanol, propanol, isopropanol or butanol) greater than 70 and up to 100% in volume).

COMPOSITIONS COMPRISING MEDIUM CHAIN TRIGLYCERIDES

Provided herein are compositions including medium chain triglycerides (MCT), methods for the preparation therefore, and methods for the use thereof. Compositions may include, for example, MCT, green coffee bean extract, and extract. Compositions described herein may be for use in, for example, weight management in a subject in need thereof. Compositions may, in certain examples, be provided as a powder mix, which may be for use as a creamer or additive for mixing with variety of beverages and/or foods. 1. A composition comprising medium chain triglycerides (MCT) and a natural sugar substitute.2. The composition according to claim 1 , wherein the MCT are triglycerides of C6 claim 1 , C8 claim 1 , C10 and/or C12 fatty acids in which the proportions of these fatty acids range in weight percent about from 0% to 2% claim 1 , 50% to 65% claim 1 , 30% to 45% claim 1 , and 0% to 3% claim 1 , respectively.3. The composition according to claim 2 , wherein the C6 fatty acid is caproic acid claim 2 , C8 fatty acid is caprylic acid claim 2 , C10 fatty acid is capric acid and C12 fatty acid is lauric acid and wherein the ratio of caprylic acid to capric acid is about 60:40.4. The composition according to claim 1 , wherein the MCT are spray dried onto a fiber carrier.5. The composition according to claim 1 , wherein the natural sugar substitute is isomaltulose.6. The composition according to claim 1 , comprising about 30% to about 65% of the MCT claim 1 , and about 0.1% to about 1.0% of the natural sugar substitute.7Irvingia. The composition according to further comprising at least one of a green coffee bean extract claim 1 , an extract and chromium.8. The composition according to which is formulated as a powder.9. A method of weight management comprising administering the composition of to a subject in need thereof.10. The method according to claim 9 , which inhibits sugar and fat absorption in the subject; enhances an energy level of the subject; and/or supports brain function ...

Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

METHODS AND COMPOSITIONS FOR WEIGHT MANAGEMENT AND FOR IMPROVING GLYCEMIC CONTROL

The present invention provides methods, compositions and modified foods and foodstuffs useful for weight management and glycemic control. 1. A modified food or foodstuff comprising an edible polymer hydrogel.248-. (canceled)49. A method of enhancing glycemic control in a subject in need thereof , comprising the step of orally administering to the subject an effective amount of an edible polymer hydrogel wherein said edible polymer hydrogel swells in the subject's stomach , the subject's small intestine or both.50. The method of claim 49 , wherein the edible polymer hydrogel is administered to the subject with food or up to two hours prior to eating.51. The method of claim 49 , wherein the edible polymer hydrogel has a swelling ratio of more than 40.52. The method of claim 49 , wherein the edible polymer hydrogel has an elastic modulus of at least 200 Pa.53. The method of claim 49 , wherein the edible polymer hydrogel has a viscosity of at least 15 s.54. The method of claim 49 , wherein the edible polymer hydrogel swells in both the stomach and small intestine of the subject.55. The method of claim 49 , wherein the edible polymer hydrogel swells in the subject's small intestine but not in the subject's stomach.56. The method of claim 55 , wherein the edible polymer hydrogel is administered with an enteric coating.57. The method of claim 49 , wherein the subject is obese claim 49 , overweight or normal weight.58. The method of claim 49 , wherein the edible polymer hydrogel is administered in an amount sufficient to increase the viscosity and elastic modulus of the gastrointestinal content and slow gastric emptying and absorption of carbohydrates and fats in the subject's small intestine.59. The method of claim 49 , wherein the polymer gel comprises a hydrophilic polymer cross-linked with a polycarboxylic acid.60. The method of claim 59 , wherein the hydrophilic polymer is an anionic polymer.61. The method of claim 60 , wherein the anionic polymer is ...

METHOD FOR PRODUCING A CHEWING GUM COMPOSITION WITH NO-BAKE CHEWING GUM

The present invention concerns a method for producing a chewing gum composition containing a fat-free and gelatin-free chewing gum, comprising the following steps: 1) preparing the liquid phase, consisting of polyol and starch syrups, 2) optionally, adding glycerin and/or emulsifier and/or flavours, 3) introducing a powder fraction consisting of non-cariogenic ingredients into the liquid phase obtained in this way, and 4) introducing the gum base, and the chewing gum composition obtained in thus way, in which the fraction of non-cariogenic ingredients comprises powdered polyols with a chosen particle size. 1. A process for producing a chewing gum composition containing a fat-free and gelatin-free chewing paste , comprising the following steps:1) preparing the liquid phase, composed of starch and polyol syrups,2) optionally, adding glycerol and/or emulsifier and/or flavorings,3) introducing into the liquid phase thus obtained a powder fraction composed of non-cariogenic ingredients, and4) introducing the gum base,characterized in that said process is carried out at a temperature of less than 100° C., preferably at a temperature of less than 90° C., in particular at a temperature of between 30-80° C., preferably between 50-80° C., for example at approximately 50° C.2. The process as claimed in claim 1 , characterized in that it comprises a step 5) of adding an additional powder fraction composed of non-cariogenic ingredients.3. The process as claimed in claim 2 , characterized in that at least 50% of the powder fraction composed of non-cariogenic ingredients is introduced in step 3) and the remainder of the powder fraction is introduced in step 5).4. The process as claimed in claim 1 , characterized in that the polyol syrups introduced into the liquid phase are chosen from maltitol claim 1 , sorbitol claim 1 , mannitol claim 1 , erythritol claim 1 , xylitol claim 1 , iditol claim 1 , isomalt and lactitol syrups claim 1 , and hydrogenated glucose syrups claim 1 , alone ...

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Prebiotic Composition and its Methods of Production

The present invention relates to a prebiotic composition comprising a galacto oligosaccharide (GOS) produced from , wherein the GOS acts as a selective growth medium for a chosen probiotic bacterial strain, and wherein the GOS is substantially the same as the form produced by reverse β-galactosidase reaction in the chosen probiotic bacterial strain. The present invention also relates to methods of producing GOS and related composition incorporating the GOS. 1LactobacillusLactobacillus plantarumLactobacillus plantarum. A selective prebiotic composition comprising a galacto oligosaccharide (GOS) produced from , wherein the GOS acts as a selective growth medium for a chosen probiotic bacterial strain , and wherein the GOS is substantially the same as the form produced by reverse β-galactosidase reaction in the chosen probiotic bacterial strain.2Lactobacillus plantarumLactobacillus plantarumLactobacillus plantarum. A composition as claimed in claim 1 , wherein the GOS is produced and/or is selective for one or more of the following bacterial strains: 2828 (ECGC 13110403); 2830 (ECGC 13110402); and 2691 (ECGC 13110401) claim 1 , or mutant strains thereof.3. A composition as claimed in claim 1 , wherein the composition is encapsulated.4. A composition as claimed in claim 1 , further comprising an excipient or carrier compound to enable it to pass through the gastrointestinal environment of the body and retain its functional properties.5. A composition as claimed in claim 1 , wherein the composition is in the form of a drinkable liquid and/or can be mixed with a solid or liquid food stuff.6. A composition as claimed in for use as a medicament.7. A composition as claimed in for use as a dietary supplement.8. A composition as claimed in for use in the management of cholesterol or in the treatment of high cholesterol.9. A composition as claimed in for use in the management or treatment of a metabolic syndrome.10. A composition as claimed in for use in weight management.11. A ...

Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof

The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.

COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET

Various aspects and embodiments disclosed herein relate generally to compositions that can be used to increase physical and mental energy, reduce the sensation of hunger. At least some of the composition disclosed herein can be used to obviate or moderate some of the discomfort which may be associated with initiating or maintaining reduced calorie and/or ketogenic diets. 1. A composition comprising:at least one beta-hydroxybutyrate salt in an amount from about 0.1 g to about 5 g; andat least one agent comprising D-Ribose.2. The composition according to claim 1 , further comprising:at least one medium chain fatty acid or ester thereof in an amount from about 0.1 g to about 10 g.3. The composition according to claim 1 , further comprising at least one compound comprising malic acid claim 1 , caffeine claim 1 , theacrine claim 1 , L-theanine claim 1 , L-tryptophan claim 1 , cannabidiol claim 1 , or a combination thereof.4. The composition according to claim 2 , wherein the at least one medium chain fatty acid or ester thereof comprises medium chain triglycerides claim 2 , coconut oil claim 2 , coconut milk powder claim 2 , fractionated coconut oil claim 2 , palm kernel oil claim 2 , isolated hexanoic acid claim 2 , isolated octanoic acid claim 2 , isolated decanoic acid claim 2 , ethoxylated triglyceride claim 2 , enone triglyceride derivatives thereof claim 2 , aldehyde triglyceride derivatives thereof claim 2 , monoglyceride derivatives thereof claim 2 , diglyceride derivatives thereof claim 2 , triglyceride derivatives thereof claim 2 , or an alkyl ester thereof.5. The composition according to claim 1 , wherein the at least one beta-hydroxybutyrate salt comprises sodium beta-hydroxybutyrate claim 1 , arginine beta-hydroxybutyrate claim 1 , potassium beta-hydroxybutyrate claim 1 , calcium beta-hydroxybutyrate claim 1 , magnesium beta-hydroxybutyrate claim 1 , lithium beta-hydroxybutyrate claim 1 , lysine beta-hydroxybutyrate claim 1 , histidine beta-hydroxybutyrate ...

Thermally inhibited waxy cassava starch

This specification discloses thermally inhibited waxy cassava starches and edible compositions made therefrom. In one aspect edible compositions have improved creaminess compared to prior art starches, independent of starch usage level and the viscosity provided by the starch. In an embodiment the edible composition comprises between 0.1% and 35.0% by weight. In various embodiments the thermally inhibited waxy cassava starch has a peak viscosity of between about 100, and 2000 Brabender units or between 500 and 1500 Brabender Units.

Water and other liquids containing hydrogen and/or noble gases

Embodiments described herein generally relate to liquids such as water containing hydrogen and a noble gas such as xenon. Such liquids may be useful, for example, for increasing a subject's physical energy levels, for improvement in athletic performance, or the like. For example, the liquid may be in the form of an energy drink. The liquids (e.g., aqueous solutions) and articles described herein may be orally administered to a subject, e.g., drunk by a subject. Some embodiments relate to liquids disposed within a container (e.g., a sealed container), such that the liquid comprises hydrogen gas and a noble gas dissolved or otherwise contained (e.g., infused) in the liquid. In certain embodiments, the hydrogen gas and/or noble gas may be present in the liquid at a particular concentration (e.g., a physiologically relevant concentration). Advantageously, the compositions, articles, and methods described herein may provide liquids containing hydrogen gas and a noble gas that are shelf-stable (e.g., maintain a relatively stable concentration of hydrogen gas and/or noble gas(es)) for relatively long periods of time (e.g., at least 7 days).

Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children

Synthetic nutritional compositions for infants and young children up to the age of thirty-six months, particularly infant formulae and growing-up milks, vary according to gender and the age of the infant or young child. The compositions have been designed to ensure balanced growth and to prevent obesity in in-fancy and later in life.

FOOD PRODUCT INCLUDING FULLY OR PARTIALLY COOKED EGG

A food product involving an integral combination of an egg layer and an edible, grain-based solid substrate can be provided by a method that involves providing a precursor product which then is heated to provide the food product. The precursor product can be provided by introducing an egg mixture to a primary surface of the edible solid substrate. The heating of the precursor converts the egg mixture into the at least partially cooked egg layer of the food product. 1. A method of making a food product that comprises an at least partially cooked egg layer and an edible , grain-based solid substrate , said method comprising:a) introducing from about 1.5 to about 3 ounces of a flowable egg-containing composition to a primary surface of said edible solid substrate, wherein the thickness of said flowable egg-containing composition is from about 0.3 to about 0.5 inches, said edible solid substrate being amenable to being handheld,b) allowing said flowable egg-containing composition to soak or wick beyond the topmost layer of said primary surface of said edible solid substrate so as to provide a food product precursor, andc) heating said food product precursor so as to convert said flowable egg-containing composition to said at least partially cooked egg layer, which is integrally connected with and bound to said substrate,thereby providing said food product.2. The method of further comprising repeating steps (a) claim 1 , (b) and (c) so as to provide a second food product and introducing said second food product to said food product so as to provide a sandwich construction.3. The method of wherein claim 1 , at the time of being introduced to said primary surface of said edible solid substrate claim 1 , said flowable egg-containing composition is at a temperature of from about 90° to about 150° F.4. The method of wherein said flowable egg-containing composition has had its temperature elevated via exposure to a kettle heater claim 3 , convection claim 3 , conduction claim ...

COMPOSITIONS COMPRISING GLUCOSE AND HEMICELLULOSE AND THEIR USE

Provided herein are purified hemicellulose compositions, sweetener compositions including purified hemicellulose compositions, as well as methods for making the same. Also provided are uses of the compositions. 1. A purified hemicellulose composition comprising:about 82% to about 92% by dry weight of xylan;about 8% to about 9% by dry weight of xylo-oligosaccharide; andabout 4% to about 5% by dry weight of xylose.2. The purified hemicellulose composition of claim 1 , wherein the purified hemicellulose composition comprises about 87% to about 88% by dry weight of xylan.3. The purified hemicellulose composition of claim 1 , wherein the purified hemicellulose composition has a molecular weight (M) of less than 4000 Da.4. The purified hemicellulose composition of claim 1 , wherein the purified hemicellulose composition has a polyphenol content of less than about 0.5% by dry weight.5. The purified hemicellulose composition of claim 1 , wherein the purified hemicellulose composition has an antioxidant level of less than about 10000 μmol TE/100 g.6. The purified hemicellulose composition of claim 1 , wherein the purified hemicellulose composition has a purity of at least 95%.7. The purified hemicellulose composition of claim 1 , wherein the xylan comprises about 90% to about 99% by dry weight of arabinoxylan.8. A food product comprising the purified hemicellulose composition of .9. A sweetener composition comprising:about 40% to about 60% by dry weight of glucose; andabout 40% to about 60% by dry weight of a purified hemicellulose.10. The sweetener composition of claim 9 , wherein the sweetener composition comprises about 45% to about 55% by dry weight of glucose.11. The sweetener composition of claim 9 , wherein the sweetener composition comprises about 45% to about 55% by dry weight of purified hemicellulose.12. The sweetener composition of claim 9 , wherein the purified hemicellulose comprises xylose claim 9 , xylo-oligosaccharide claim 9 , and xylan.13. The sweetener ...

Novel Lactobacillus and Composition for Preventing, Improving, or Treating Degenerative Brain Diseases or Cognitive Function Disorders

The present invention provides a novel lactobacillus and a use for same, the lactobacillus being separated from kimchi and thus highly safe, and having various types of biological activity such as memory improving activity, tight junction protein expression inducing activity, antioxidation activity, lipopolysaccharide (LPS) generation-suppressing activity, and β-glucuronidase inhibiting activity. The novel lactobacillus according to the present invention may be used as a functional food medicine material for preventing, improving, or treating degenerative brain diseases or cognitive function disorders.

LACTOBACILLUS CASEI FOR TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS

The strain AH077 (NCIMB12019) produces a polysaccharide and increases energy excretion. The strain acts to block fat absorption and is used in the prevention or treatment of obesity and obesity-related metabolic syndrome. 126-. (canceled)27Lactobacillus casei. A strain of AH077 deposited with the NCIMB under accession number 42019.28. The strain as claimed in in the form of viable cells.29. The strain as claimed in in the form of non-viable cells.30Lactobacillus casei. A formulation which comprises a strain of AH077 deposited with the NCIMB under accession number 42019.31. The formulation as claimed in which further comprises a probiotic material.32. The formulation as claimed in which further comprises a prebiotic material.33. The formulation as claimed in further comprising an ingestible carrier.34. The formulation as claimed in wherein the ingestible carrier comprises a pharmaceutically acceptable carrier chosen from a capsule claim 29 , a tablet claim 29 , or a powder.35. The formulation as claimed in wherein the ingestible carrier comprises a food product chosen from acidified milk claim 29 , yoghurt claim 29 , frozen yoghurt claim 29 , milk powder claim 29 , milk concentrate claim 29 , cheese spreads claim 29 , dressings claim 29 , or beverages.36. The formulation as claimed in which further comprises at least one of a protein or a peptide rich in glutamine/glutamate claim 29 , a lipid claim 29 , a carbohydrate claim 29 , a vitamin claim 29 , a mineral claim 29 , a trace element claim 29 , or a combination thereof.37. The formulation as claimed in wherein the strain is present in an amount of more than 10cfu per gram of the formulation.38. The formulation as claimed in which further comprises one or more of an adjuvant claim 29 , a bacterial component claim 29 , a drug entity claim 29 , or a biological compound.39Lactobacillus casei. A freeze dried composition comprising the strain of AH077 of .40Lactobacillus casei. A foodstuff comprising the strain of AH077 ...

NOVEL USE OF PINOCARVEOL

The present invention relates to a pharmaceutical composition comprising pinocarveol for preventing or treating metabolic diseases, and functional food composition using the pharmaceutical composition for improving or alleviating metabolic diseases. Pinocarveol according to the present invention reduces weight, visceral fat, and cholesterol concentration, improves blood liver function index, reduces blood sugar, and additionally inhibits a metabolic inflammation reaction, and thus can be effectively used ultimately as a medical or functional food composition exhibiting prevention or treatment activities for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and syndromes of fatty liver and insulin-resistance. 1. A pharmaceutical composition for preventing or treating a metabolic disease , comprising:pinocarveol as an active ingredient,wherein the metabolic disease is selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver, and insulin resistance syndrome.2. The pharmaceutical composition of claim 1 , wherein the dyslipidemia is hyperlipidemia.3. The pharmaceutical composition of claim 1 , wherein the fatty liver is non-alcoholic fatty liver.4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces body weight or diet efficiency.5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces visceral fat.6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces a plasma lipid concentration.7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces liver weight or a lipid concentration in a liver tissue.8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces alanine aminotransferase (ALT) activity or aspartate aminotransferase (AST) activity in blood.9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical ...

Lipid metabolism-promoting composition including isoxanthohumol

The present invention aims to provide a composition for promoting lipid metabolism, a composition for suppressing fat accumulation, and the like, which contain, as an active ingredient, a substance that is thermally stable and adequately water-soluble and that has lipid metabolism-promoting action. The present invention relates to a composition for promoting lipid metabolism containing isoxanthohumol.

Nutritional compositions for controlling blood glucose level

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and/or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

Lipid supplements for maintaining health and treatment of acute and chronic disorders

Nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprise enriched formulations of phospholipids and chemical precursors containing specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. Methods of enriching extracted sources of cell and mitochondrial membrane molecules and precursors from microbes, plants and other sources are also set forth. The formulae can be combined with nutritional, prebiotic, and probiotic (microbial) factors that increase bioavailability through the digestive tract and increase absorption at the cellular and subcellular levels. These lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms. The various combinations specifically enriched in the correct phospholipid and correct fatty acid residues can be used to treat organ, tissue, cell or system.

Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication

The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.